

CURRICULUM VITAE

JEFFREY K ARONSON

November 2012

CONTENTS

Personal details	2
Qualifications	2
Prizes and awards	2
Current appointments	2
Visiting professorships	2
Previous appointments	3
Editorial and journalistic activities	3–4
Other activities (current and past)	
National committee memberships	4
Oxford University	4–5
Oxfordshire Health Authority/Oxford Radcliffe Hospitals (ORH) Trust	5
Meetings organized	5
Membership and fellowship of academic societies	5
Teaching and examinations	5
Internal examiner	5
External examiner	6
Lectures	6
Research	
Current research interests	7
Research and thesis supervision	7
Patent	7
Publications 1975–2012	
Top ten cited papers	8
A Original papers and reports	8–13
B Books and edited journal issues	14–15
C Editorial reviews and commentaries—general	15–16
D Editorial commentaries—British Journal of Clinical Pharmacology	16–18
E Book chapters and reviews	18–24
F Presentations to learned societies, letters to journals, other occasional pieces	24–28
G Medical language	28–30
H Medical humanities	30–31
J Book reviews etc	31–32

PERSONAL DETAILS

Date of birth: [REDACTED]
Nationality: [REDACTED]
Work address: Oxford University Department of Primary Care Health Sciences
New Radcliffe House, Radcliffe Observatory Quarter,
Woodstock Road, Oxford OX2 6GG
GMC registration number: [REDACTED]
Telephone (admin): [REDACTED]
Fax: [REDACTED]
E-mail (best method): [REDACTED]
Web site: http://www.primarycare.ox.ac.uk/dept_staff/jeffaronson

QUALIFICATIONS

MB ChB Glasgow University, 1970
MRCP (UK) 1973
DPhil Oxford University (Corpus Christi College), 1977 [Studies on the clinical pharmacology of cardiac glycosides]
MA Oxford University, 1984
FRCP Royal College of Physicians, 1985
FBPharmacolS British Pharmacological Society, 2004
FFPM (Hon) Faculty of Pharmaceutical Medicine of the RCP, 2007

PRIZES AND AWARDS

University Distinction in Materia Medica (Glasgow University), 1967
First prize, annual Scottish Chest and Heart Association competition, 1968
Nuffield Bursary, Middlesex Hospital, August–December 1969
Paul Martini Prize, for the development of methods for evaluation in the fields of clinical pharmacology and therapeutics, 1980
Australasian Visitor, British Pharmacological Society, 1985
Smith, Kline and French Foundation Travelling Prize for Research in Clinical Pharmacology (awarded by the British Pharmacological Society), 1988

CURRENT APPOINTMENTS

Reader in Clinical Pharmacology, Oxford University, Department of Primary Health Care
Honorary Consultant in Clinical Pharmacology and Honorary Consultant Physician, Oxford University Hospitals NHS Trust

VISITING PROFESSORSHIPS

December 1991 University of Ceará, Brazil
November 1997 University of Kentucky, Louisville
November 2000 University of Colombo, Sri Lanka

PREVIOUS APPOINTMENTS

August 1970–January 1971	Junior Medical House Officer, Southern General Hospital, Glasgow
February 1971–July 1971	Junior Surgical House Officer, Victoria Infirmary, Glasgow
August 1971–April 1973	Senior Medical House Officer, Stobhill Hospital, Glasgow
May 1973–August 1973	Medical Registrar, Stobhill Hospital, Glasgow
September 1973–October 1980	Member of Scientific Staff, MRC Unit and University Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford
September 1973–August 1977	Honorary Registrar in Clinical Pharmacology, Oxfordshire Health Authority
September 1977–October 1980	Honorary Senior Registrar in Clinical Pharmacology, Oxfordshire Health Authority
August 1979–October 1980	Senior Registrar in General Medicine, Oxfordshire Health Authority
November 1980–October 1984	Wellcome Lecturer and Consultant in Clinical Pharmacology, University of Oxford
November 1984–December 1993	Reader and Consultant in Clinical Pharmacology (Wellcome Lecturer), University of Oxford

EDITORIAL AND JOURNALISTIC ACTIVITIES

Guest Editor, Clinical Medicine (RCP) issue on CME in Clinical Pharmacology, 2009
Editor-in-Chief, British Journal of Clinical Pharmacology, 2002–7
Guest Editor, BMJ special issue: “Balancing benefits and harms in health care”, 3 July 2004
Editor, British Journal of Clinical Pharmacology special issues: “Citation Classics in the British Journal of Clinical Pharmacology, 1974–2003”, December 2004 ; “Clinical Pharmacology: Past, Present, and Future”, June 2006 ; “Adverse Drug Reactions”, February 2007 ; “Medication Errors”, June 2009 ; “An Agenda for UK Clinical Pharmacology”, June 2012.
Member, Advisory Editorial Board, Oxford Today (editor Georgina Ferry), 2002–7
Co-editor-in-chief, Meyler's Side Effects of Drugs, 14th edition, 2000
Editor, Meyler's Side Effects of Drugs—The International Encyclopedia of Adverse Drug Reactions and Interactions, 15th edition (six-volume encyclopedia and web version), 2006; 16th edition in preparation
Editor, Side Effects of Drugs Annuals, Volumes 15–34, 1991–2012; Volume 35, 2013, in preparation
Managing Editor, The European Journal of Clinical Pharmacology, 1985–93; Reviews Editor, 1994–2002
Chairman of the Committee of Management, Prescribers' Journal, 1994–6 (Vice-Chairman, 1992–4; Member 1990–6)
Member of the Editorial Advisory Panel, Prescribers' Journal, 1996–2000
Member of the Board of Management, Reuters Journalists' Fellowship Programme, 1992–2005
Member of the Editorial Boards of:
Clinical Science, 1984–8
The British Journal of Clinical Pharmacology, 1986–91, 2000–7

Archives Internationales de Pharmacodynamie et de Thérapie, 1976–96
 The Wellness Letter, 1992–3
 Adverse Drug Reactions Bulletin, 1996–
 Cases Journal, 2008–10
 Regular referee for numerous bioscience journals, including the BMJ, The Lancet, Drug Safety
 Consultant on medical and pharmacological words, Collins English Dictionary, editions 6–10

OTHER ACTIVITIES (current and past)

National committees and learned societies

President Emeritus, British Pharmacological Society 2010– (President 2008–9; President-elect 2006–7); Trustee, Member of Council, and Member of the Executive Committee, 2002–9;
 Member, Advisory Board of the British National Formulary, 2012–
 Member, NIHR Journals Library Board, 2012–
 Member, Advisory Board (RCP representative), NHS Evidence, 2010–12
 Member, Task and Finish Working Group of the HE/Industry Forum of the Office for Life Sciences, 2009–10
 Member, Advisory Board (RCP representative), National Patient Safety Agency, 2009–2010
 Member, Board of ‘Prescribe’, Department of Health, e-Learning for Health, 2009–2010
 Member of Technology Appraisal Committee, NICE, 2006–
 Member, Joint Formulary Committee of the British National Formulary, 2006–2012
 Chairman of the British Pharmacopoeia’s Expert Advisory Group on Nomenclature, 2006– (member 1995–2006)
 Member of the Health Technology Assessment’s Commissioning Board, 2003–7
 Member, Steering Group for the British National Formulary for Children, 2003–4; Paediatric Formulary Committee 2004–12
 Vice Chairman, Medicines Commission, 2002–5 (Member 2001–5)
 Chairman, Joint (CSM and Medicines Commission) Working Group on the Prescribing, Supply and Administration of Medicines (2002–4)
 Member of the Wellcome Trust’s History of Medicine Grants and Units Panel [from 1998 Grants Panel], 1993–2000 (Deputy Chairman 1996–2000); Chairman, quinquennial review of the London History of Medicine Unit, 2000
 Member of the Wellcome Trust’s Medicine, Society, and History Committee (previously History of Medicine Committee), 1993–2000
 Member of the Medical Research Council’s Committee on Therapeutic Trials in AIDS and chairman of its Subgroup on New Therapeutic Agents, 1987–93

Oxford University

Associate Member, Department of Pharmacology, 2009–
 Head of Department, University Department of Clinical Pharmacology, 1990–1, 2000–1
 Fellow of Green College, 1984–2008 (Tutor for Admissions, 1986–8; Senior Tutor 1994–7)
 Fellow of Green-Templeton College, 2008–
 Visitor of the Museum for the History of Science, 2003–7
 Member of the Division of Medical Sciences, 2000–
 Member of the Management Committee of the Wellcome Unit for the History of Medicine, 2000–5
 Member of the Committee for the History of Science, Medicine, and Technology, 2000–5
 Honorary Associate Member, Wellcome Unit for the History of Medicine, 1998–
 Member of the Board of the Faculty of Clinical Medicine 1997–2000

Curator of the Bodleian Library, 1995–9
 Clinical representative on the core curriculum committee (preclinical), 1995–8, and its physiology and pharmacology subcommittee, 1998–2008
 University representative on the liaison committee of the Oxford University SmithKline Beecham Centre for Applied Neuropsychobiology, 1990–9
 Oxford University Assessor, 1989–90
 Member of the Management Board for Library Services to the Faculty Board of Clinical Medicine, 1994–7
 Member of the Libraries' Board, 1994–7
 Member of the Applications Committee of the Faculty Board of Clinical Medicine, 1993–5
 Member of the International Committee, 1992–9
 Member of the Board of Management of the Astor Fund, 1992–2001
 Member of the Committee for the Admission of Medical Students to the Oxford Medical School, 1985–8

Oxfordshire Health Authority/Oxford Radcliffe [now Oxford University] Hospitals (ORH/OUH) Trust

Regional SAC representative for Clinical Pharmacology and Therapeutics, 2000–
 Deputy Chairman, Medicines Advisory Committee (previously Drug and Therapeutics Committee), ORH/OUH Trust, 1980–2001; Member, 2001–
 Member of the ORH Trust's Technology Advisory Group, 2002–6
 University representative on the Executive Board of the ORH Trust, 2001–2
 Member of the ORH Trust's Discretionary Awards Committee, 1998–2001
 Member of the Clinical Research Subcommittee of the Anglia and Oxford Regional Health Authority, 1995–9
 Member of the Oxfordshire Health Authority's Medical Advisory Group, 1993–5
 On-take physician, ORH Trust, 1992–2008
 Member of the Central Oxford Research Ethics Committee (now OXREC), 1982–6 (Chairman 1984–6)

Meetings organized

Co-founder (with JC Ellory): Oxford Ion Transport Club (organizer 1989–92)
 Organizer: Penicillin 50 Symposium, Oxford 1991
 Organizer: James Black Meeting—Planning a 5-year agenda for UK clinical pharmacology, Oxford 2011
 Organizer (with Giampaolo Vello): The Future of European Clinical Pharmacology and Therapeutics, Erice, June 2012

MEMBERSHIP & FELLOWSHIP OF ACADEMIC SOCIETIES

Fellow of the British Pharmacological Society, 2004– (Member 1977–2003), Member of the Committee of its Clinical Section, 1985–9; Trustee and Member of Council, 2002–9; President-elect, 2006–7; President 2008–9, President Emeritus 2010–
 Member of the Medical Research Society, 1984–
 Fellow of the Royal College of Physicians, 1985–
 Member of the Association of Physicians of Great Britain and Ireland, 1988 – (Senior Member 2007–)
 Member of the Medical Society of London, 2002–
 Honorary Fellow of the Faculty of Pharmaceutical Medicine, 2007–

TEACHING AND EXAMINATIONS

Undergraduate and postgraduate teaching activities include numerous lectures on drug therapy to clinical students, regular bedside/seminar teaching on drug therapy and clinical medicine to clinical students, regular drug therapy presentations ("Prescription of the Week") at the weekly Grand Round and Student Grand Round, and seminars and lectures on drug therapy for GPs, specialists, doctors in training, nurses, and pharmacists.

Internal examiner

First BM examinations 1994–6 (Chairman of Examiners, 1995–6); 2000–2

Frequent examiner of DM, DPhil, and MSc theses

External examiner/adviser

Programme and Module External Examiner, Pan-European MSc in Pharmacovigilance and Pharmacoepidemiology (Barcelona, Bordeaux, Hertfordshire, Rotterdam, Utrecht, Verona), 2011–

Appointments panel, Chair of Clinical Pharmacology, Lausanne, 2011

Clinical Pharmacology (MSc), Aberdeen, 2004–6

Pharmacology & Therapeutics (BMedSci), Sheffield, 1996

Clinical Pharmacology (MBChB), Sheffield, 1994–6

Pharmacology (MBBS), Cardiff, 1990–3

Pharmacology and Clinical Pharmacology & Therapeutics, London University (BSc and MBBS, various medical schools), 1983–92; 1998–2000

MD/PhD theses: Liverpool, 1987; Cambridge, 1990; Hong Kong, 1991; Leicester, 1993; Otago, NZ, 1995; QMUL, London, 2009)

LECTURES

Numerous invited national and international lectures, including the following named and plenary lectures:

SKF Prize Lecture (British Pharmacological Society), 1989: Blood and ions.

Lettsomian Lecture (Medical Society of London), 2003: John Cookley Lettsom and the introduction of digitalis into clinical practice at the end of the eighteenth century. *Trans Med Soc Lond* 2002-3; 119: 77-85. [PMID: 17184033]

Lord Cohen Lecture, Liverpool, 2006: The demedicalization of prescribing.

John Ash Lecture, Birmingham, 2006: "A direct contrary road"—medical disputation in John Ash's Birmingham

FitzPatrick Lecture, Royal College of Physicians, London, 2007: "Clinical pharmacology: a suitable case for treatment" https://admin.emea.europa.eu/~/media/EMA/PDFs/2007/05/2007_05_23_FitzPatrick_Lecture.pdf

ASCEPT (Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists), Adelaide, 2007: Plenary lectures: "Classifying adverse drug reactions—from dichotomy to polytomy"; "Lessons from Vioxx: a regulatory approach to problematic drugs—joining the DoTS"

Gideon de Laune Lecture, Society of Apothecaries, London, 2008: "PoM to P: selling medicines to patients" *BMJ* 2009; 339: b5415. [PMID: 20008435]

EUFEPS (European Federation of Pharmaceutical Sciences), Verona, 2008: "The law of life. How do clinicians perceive and act on variability in drug response?"

Adverse Drug Reactions Monitoring Centre, Uppsala, 2008: "Aristotle's prior knowledge—the general approach to definition and its relevance to signal detection in drug safety"

ESCOMP (European Society for Patient Adherence, Compliance, and Persistence), Bangor, 2009: "Adding PEP to prescribing—the definitive method"

President's Lecture (British Pharmacological Society), London, 2009 : "Clinical Pharmacology—Past, Present, and (YES) Future"

WorldPharma, Copenhagen 2010. Opening plenary lecture. "Found in translation. Human pharmacology and applied pharmacology come of age" <http://www.bps.ac.uk/SpringboardWebApp/userfiles/bps/file/Meetings/WPJAransonFoundInTranslationLecture.pdf>.

Nobel Symposium, Karolinska Institute, 2010. "Sex, gender, and pharmacology. The UK and European experience" <http://www.informationsteknikstreaming.se/sll/101019>.

International Society of Pharmacovigilance, Istanbul, 2011. Plenary lecture: " 'Better than cure': assessing the preventability of adverse drug reactions"

International Society of Pharmacovigilance, Cancun, 2012. Plenary lecture: "The Law of Mass Action: Relevance to pharmacovigilance"

RESEARCH

Current research interests

Methods of classifying, detecting, and reporting adverse drug reactions, including systematic reviews, meta-analyses, and the use of anecdotal reports (including collaborations with Professor RE Ferner, Birmingham, Dr M Hauben, New York, and others)

Innovation in drug therapy (collaboration with Professor RE Ferner, University of Birmingham, and Professor DA Hughes, University of Bangor)

Monitoring therapy in chronic disease (collaboration with Professor Paul Glasziou, Department of Primary Health Care, Oxford, and others)

Philosophy of evidence-based medicine (collaboration with Dr Jeremy Howick and Professor Paul Glasziou, Department of Primary Health Care, Oxford)

Simple and cheap methods of medical management of toxicological problems in Sri Lanka (collaboration with HA de Silva and colleagues, University of Colombo, Sri Lanka)

Developing a toolkit for patient safety in general practice (collaboration with Professor Tony Avery, Nottingham, and others)

Research and thesis supervision

Numerous MD, DPhil, and MSc students, 1977–

Patent

Aronson J K, De Silva H A, Graham-Smith D G. US Patent No. 6,087,118. Method for diagnosing Alzheimer's disease.

PUBLICATIONS 1975–2012

Top ten cited articles (according to the Web of Knowledge; h index 32):

- 443: Edwards IR, Aronson JK. Adverse drug reactions—definitions, classification, diagnosis, management, surveillance. *Lancet* 2000; 356: 1255-60. [PMID: 11072960]
- 138: Willoughby PB, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. *Gut* 1982; 23(12): 1081-7. [PMID: 7173720]
- 89: Aronson JK. Clinical pharmacokinetics of digoxin 1980. *Clin Pharmacokin* 1980; 5(2): 137-49. [PMID: 6988136]
- 77: Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJM, Aronson JK, Grahame-Smith DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. *Br J Clin Pharmacol* 1996; 42(4): 423-9. [PMID: 8904613]
- 68: Barkun JS, Aronson JK, Feldman LS, Madder GJ, Strasberg SM; Balliol Collaboration, Altman DG, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Flum DR, Glasziou P, Marshall JC, McCulloch P, Nicholl J, Reeves BC, Seiler CM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Locke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Evaluation and stages of surgical innovations. *Lancet* 2009; 374(9695): 1089-96. [PMID: 19782874]
- 68: Aronson JK, Ferner RE. Joining the DoTS. New approach to classifying adverse drug reactions. *BMJ* 2003; 327: 1222-5. [PMID: 14630763]
- 67: Aronson JK, Grahame-Smith DG, Hallis KF, Hibble AG, Wigley FM. Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. *Br J Clin Pharmacol* 1977; 4: 213-21. [PMID: 861136]
- 65: Aronson JK, Dengler HJ, Dettli L, Follath F. Standardization of symbols in clinical pharmacology. *Eur J Clin Pharmacol* 1988; 35: 1-7. [PMID: 3220089]
- 61: Ford AR, Aronson JK, Grahame-Smith DG, Carver JG. The acute changes seen in cardiac glycoside receptor sites, ⁸⁶Rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. *Br J Clin Pharmacol* 1979; 8: 135-42. [PMID: 486290]
- 54: Nobel CSI, Aronson JK, Døbbelsteen DJ, Slater AFG. Inhibition of Na⁺/K⁺-ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. *Apoptosis* 2000; 5: 153-63. [PMID: 11232243]

A Original papers and reports

1. Aronson JK, Grahame-Smith DG. Digoxin therapy: textbooks, theory and practice. *Br J Clin Pharmacol* 1976; 3(4): 639-48. [Correction in: *Br J Clin Pharmacol*. 1976 October; 3(5): i3.] [PMID: 22216507]
2. Aronson JK, Grahame-Smith DG. Altered distribution of digoxin in renal failure—a cause of digoxin toxicity? *Br J Clin Pharmacol* 1976; 3(6): 1045-51. [PMID: 22216528]
3. Aronson JK, Grahame-Smith DG, Hallis KF, Hibble AG, Wigley FM. Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. *Br J Clin Pharmacol* 1977; 4(2): 213-21. [PMID: 861136]
4. Aronson JK, Grahame-Smith DG. Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. *Br J Clin Pharmacol* 1977; 4(2): 223-7. [PMID: 861137]
5. Aronson JK. Monitoring digoxin therapy: III. How useful are the nomograms? *Br J Clin Pharmacol* 1978; 5(1): 55-64. [PMID: 619935]
6. Aronson JK, Grahame-Smith DG, Wigley FM. Monitoring digoxin therapy: the use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. *Q J Med* 1978; 47(186): 111-12. [PMID: 684152]
7. Williams P, Aronson JK, Sleight P. Is a slow pulse rate a reliable sign of digitalis toxicity? *Lancet* 1978; 2(8104-5): 1340-2. [PMID: 82842]
8. Youdim MBH, Aronson JK, Blau K, Green AR, Grahame-Smith DG. Tranlycypromine ('Parnate') overdose: measurement of tranlycypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. *Psychol Med* 1979; 9(2): 377-82. [PMID: 472083]
9. Ford AR, Aronson JK, Grahame-Smith DG, Rose JA. The characteristics of the binding of 12-³H-digoxin to the membranes of intact human erythrocytes. *Br J Clin Pharmacol* 1979; 8(2): 115-24. [PMID: 486288]

10. Ford AR, Aronson JK, Grahame-Smith DG, Carver JG. Changes in cardiac glycoside receptor sites, ⁸⁶rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. *Br J Clin Pharmacol* 1979; 8(2): 125-34. [PMID: 486289]
11. Ford AR, Aronson JK, Grahame-Smith DG, Carver JG. The acute changes seen in cardiac glycoside receptor sites, ⁸⁶rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy. *Br J Clin Pharmacol* 1979; 8(2): 135-42. [PMID: 486290]
12. Aronson JK, Ford AR. The use of colour vision measurement in the diagnosis of digoxin toxicity. *Q J Med* 1980; 49(195): 273-82. [PMID: 6970370]
13. Green AR, Aronson JK, Curzon G, Woods HF. Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. *Br J Clin Pharmacol* 1980; 10(6): 603-10. [PMID: 6162471]
14. Green AR, Aronson JK, Curzon G, Woods HF. Metabolism of an oral tryptophan load. II: Effect of pretreatment with the putative pyrrolase inhibitors nicotinamide or allopurinol. *Br J Clin Pharmacol* 1980; 10(6): 611-15. [PMID: 6451235]
15. Green AR, Aronson JK. Metabolism of an oral tryptophan load. III: Effect of a pyridoxine supplement. *Br J Clin Pharmacol* 1980; 10(6): 617-19. [PMID: 7470373]
16. Aronson JK, Geaney DP, Grahame-Smith DG, Carver JG, Hallis KF. Lack of effect of phenytoin on functions related to Na^+, K^+ -ATPase activity in the intact erythrocytes of epileptic patients. *Br J Clin Pharmacol* 1981; 12(1): 79-81. [PMID: 6264938]
17. Azad Khan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. *Br J Clin Pharmacol* 1982; 13(4): 523-8. [PMID: 6121576]
18. Zannad F, Graham CW, Aronson JK. The effect of digoxin and dopamine on the oxygen consumption, lactate production and haemodynamic performance of an isolated, perfused, working guinea-pig heart. *Eur J Pharmacol* 1982; 81(2): 263-71. [PMID: 7117376]
19. Geaney DP, Carver JG, Aronson JK, Warlow C. Interaction of phenytoin with azapropazone. *Br Med J (Clin Res Ed)* 1982; 284(6326): 1373. [PMID: 6803981]
20. Willoughby PB, Aronson JK, Agback H, Bodin NO, Truelove SC. Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. *Gut* 1982; 23(12): 1081-7. [PMID: 7173720]
21. Geaney DP, Carver JG, Davies CL, Aronson JK. Pharmacokinetic investigation of the interaction of azapropazone with phenytoin. *Br J Clin Pharmacol* 1983; 15(6): 727-34. [PMID: 6871071]
22. Boon NA, Rose JA, Hallis KF, Jones JV, Manley BS, Aronson JK. Evidence that cation transport is reduced in one-kidney one clip hypertension. *J Hypertens Suppl* 1983; 1(2): 129-31.
23. Boon NA, Aronson JK, Hallis KF, White NJ, Raine AEG, Grahame-Smith DG. A method for the study of cation transport in vivo: effects of digoxin administration and of chronic renal failure on the disposition of an oral load of rubidium chloride. *Clin Sci (Lond)* 1984; 66(5): 569-74. [PMID: 6705481]
24. Aronson JK, Moore MP, Redman CWG, Harper C. Erythrocytic cation transport receptor numbers and activity in pregnancies complicated by essential hypertension and pre-eclampsia. *Br Med J (Clin Res Ed)* 1984; 288(6427): 1332-4. [PMID: 6424846]
25. Boon NA, Oh VMS, Taylor EA, Johansen T, Aronson JK, Grahame-Smith DG. Measurement of specific [³H]-ouabain binding to different types of human leucocytes. *Br J Clin Pharmacol* 1984; 18(2): 153-61. [PMID: 6487454]
26. Boon NA, Aronson JK, Hallis KF, Raine AEG, Grahame-Smith DG. An in vivo study of cation transport in essential hypertension. *J Hypertens Suppl* 1984; 2(3): S457-9. [PMID: 6100748]
27. Boon NA, Harper C, Aronson JK, Grahame-Smith DG. Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. *Clin Sci (Lond)* 1985; 68(5): 511-15. [PMID: 3979014]
28. Hallis KF, Boon NA, Perkins CM, Aronson JK, Grahame-Smith DG. A sensitive high-temperature electrothermal atomic absorption analysis of Rb^+ in erythrocytes and plasma of normal and hypertensive persons. *Clin Chem* 1985; 31(2): 274-6. [PMID: 3967362]
29. Green AR, Aronson JK, Cowen PJ. The pharmacokinetics of L-tryptophan following its intravenous and oral administration. *Br J Clin Pharmacol* 1985; 20(4): 317-21. [PMID: 4074600]
30. Boon NA, Aronson JK, Hallis KF, Grahame-Smith DG. Cation transport abnormalities in vivo in untreated essential hypertension. *Clin Sci (Lond)* 1986; 70(6): 611-16. [PMID: 3709067]
31. Boon NA, Pugh SE, Hallis KF, Aronson JK, Grahame-Smith DG. In vivo cation transport during short-term and long-term digoxin therapy. *Br J Clin Pharmacol* 1986; 22(1): 27-30. [PMID: 3741723]
32. Rapeport WG, Aronson JK, Grahame-Smith DG, Harper C. The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [³H]-ouabain binding to human lymphocytes after incubation for 3 days. *Br J Clin Pharmacol* 1986; 22(3): 275-9. [PMID: 3768239]

33. Oh V MS, Taylor E A, Ding J L, Boon N A, Aronson J K, Grahame-Smith D G. Enhancement of specific ouabain binding and ouabain-sensitive ^{86}Rb uptake in intact human lymphocytes by a dialysable factor in human and fetal calf sera. *Clin Sci (Lond)* 1987; 72(1): 71-9. [PMID: 2879663]
34. Wood AJ, Viswalingam A, Glue P, Aronson JK, Grahame-Smith DG. Measurement of cation transport in vivo in healthy volunteers after the oral administration of lithium carbonate. *Clin Sci (Lond)* 1989; 76(4): 397-402. [PMID: 2540932]
35. Wood AJ, Aronson JK, Bunch C, Grahame-Smith DG. A study of the transport of lithium across the erythrocyte membrane in vivo and of the effects of the ion transport inhibitors digoxin and dipyrindamole. *Br J Clin Pharmacol* 1989; 27(6): 749-56 [PMID: 2757891]
36. Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Bloomfield J G. Clinical, haemodynamic, and pharmacological effects of withdrawal and reintroduction of digoxin in patients with heart failure in sinus rhythm after long-term treatment. *Br Heart J* 1989; 61(6): 529-39. [PMID: 2503017]
37. Wood A J, Elphick M, Aronson J K, Grahame-Smith D G. The measurement of transmembrane cation transport in vivo in acute manic illness. *Br J Psychiatry* 1989; 155: 501-4. [PMID: 2558772]
38. Wood A J, Elphick M, Aronson J K, Grahame-Smith D G. The effect of lithium on cation transport measured in vivo in patients suffering from bipolar affective illness. *Br J Psychiatry* 1989; 155: 504-10. [PMID: 2558773]
39. Syme PD, Dixon RM, Allis JL, Aronson JK, Grahame-Smith DG, Radda GK. A non-invasive method of measuring concentrations of rubidium in rat skeletal muscle in vivo by ^{87}Rb nuclear magnetic resonance spectroscopy: implications for the measurement of cation transport activity in vivo. *Clin Sci (Lond)* 1990; 78(3): 303-9. [PMID: 2156650]
40. Wood AJ, Brearley CJ, Aronson JK, Grahame-Smith DG. The effect of oral salbutamol on cation transport measured in vivo in healthy volunteers. *Br J Clin Pharmacol* 1990; 30(3): 383-90. [PMID: 2171617]
41. Kennedy DG, Aronson J K, Bloomfield J G, Grahame-Smith D G. The effects of a low extracellular concentration of potassium on the activity and numbers of Na^+/K^+ pumps in an EB-virus transformed human lymphocyte cell line. *Biochim Biophys Acta* 1990; 1027(3): 218-24. [PMID: 1975752]
42. Syme PD, Arnold L, Green Y, Aronson JK, Grahame-Smith DG, Radda GK. Evidence for increased in vivo Na^+/H^+ antiporter activity and an altered skeletal muscle contractile response in the spontaneously hypertensive rat. *J Hypertens* 1990; 8(11): 1027-36. [PMID: 1963185]
43. Syme P D, Dixon R M, Aronson J K, Grahame-Smith D G, Radda G K. Evidence for increased in vivo sodium-potassium pump activity and potassium efflux in skeletal muscle of spontaneously hypertensive rats. *J Hypertens* 1990; 8(12): 1161-6. [PMID: 1962807]
44. Moraes MEA, Aronson JK, Grahame-Smith DG. Intravenous strontium gluconate as a kinetic marker for calcium in healthy volunteers. *Br J Clin Pharmacol* 1991; 31(4): 423-7. [PMID: 2049251]
45. Wood AJ, Smith CE, Clarke EE, Cowen PJ, Aronson JK, Grahame-Smith DG. Altered in vitro adaptive responses of lymphocyte Na^+/K^+ -ATPase in patients with manic depressive psychosis. *J Affect Disord* 1991; 21(3): 199-206. [PMID: 1648581]
46. Davies JE, Ng LL, Ameen M, Syme PD, Aronson JK. Evidence for altered Na^+/H^+ antiporter activity in cultured skeletal muscle cells and vascular smooth muscle cells from the spontaneously hypertensive rat. *Clin Sci (Lond)* 1991; 80(5): 509-16. [PMID: 1851693]
47. Jenkins RJ, Aronson JK, Brearley CJ. Increases in Na/K pump numbers in isolated human lymphocytes exposed to lithium in vitro. Reversal by myo-inositol and by inhibitors of protein kinase C and the Na/H antiporter. *Biochim Biophys Acta* 1991; 1092(2): 138-44. [PMID: 1850301]
48. Syme PD, Brunotte F, Green Y, Aronson JK, Radda GK. The effect of β_2 -adrenoceptor stimulation and blockade of L-type calcium channels on in vivo Na^+/H^+ antiporter activity in rat skeletal muscle. *Biochim Biophys Acta* 1991; 1093(2-3): 234-40. [PMID: 1650580]
49. Moraes MEA, Aronson JK, Grahame-Smith DG. The effect of nifedipine on the disposition of strontium gluconate used as a kinetic marker for calcium in healthy volunteers. *Br J Clin Pharmacol* 1991; 32(4): 441-5. [PMID: 1958437]
50. Syme PD, Aronson JK, Thompson CH, Williams E M, Green Y, Radda GK. Na^+/H^+ and $\text{HCO}_3^-/\text{Cl}^-$ exchange in the control of intracellular pH in vivo in the spontaneously hypertensive rat. *Clin Sci (Lond)* 1991; 81(6): 743-50. [PMID: 1662580]
51. Ameen M, Bloomfield J G, Aronson JK. Reversal of the effects of a low extracellular potassium concentration on the number and activity of Na^+/K^+ pumps in an Epstein-Barr virus-transformed human lymphocyte cell line. *Biochem Pharmacol* 1992; 43(3): 489-96. [PMID: 1311581]
52. Antia I J, Driskins CE, Wood A J, Aronson J K. Increase in Na^+/K^+ pump numbers in vivo in healthy volunteers taking oral lithium carbonate and further upregulation in response to lithium in vitro. *Br J Clin Pharmacol* 1992; 34(6): 535-40. [PMID: 1337260]
53. Crotty B, Rosenberg WM, Aronson J K, Jewell D P. Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease. *Gut* 1992; 33(10): 1353-7. [PMID: 1446859]

54. Brearley CJ, Wood AJ, Aronson JK, Grahame-Smith DG. Evidence for an altered mode of action of the sodium/lithium countertransporter in vivo in patients with untreated essential hypertension. *J Hypertens* 1993; 11(2): 147-53. [PMID: 8385174]
55. Aronson JK, Chappell MJ, Godfrey KR, Yew MK. Modelling circadian variation in the pharmacokinetics of non-steroidal anti-inflammatory drugs. *Eur J Clin Pharmacol* 1993; 45(4): 357-61. [PMID: 8299670]
56. Brearley CJ, Aronson JK, Boun NA, Raine AEG. Effects of haemodialysis and continuous ambulatory peritoneal dialysis on abnormalities of ion transport in vivo in patients with chronic renal failure. *Clin Sci (Lond)* 1993; 85(6): 725-31. [PMID: 8287666]
57. Aronson JK. What's in a brand name? *BMJ* 1994; 308(6937): 1140-1. [PMID: 8173456]
58. Aronson JK. The imp in the bottle. *Practitioner* 1994; 238(1544): 792-4. [PMID: 7991498]
59. Antia IJ, Smith CE, Wood AJ, Aronson JK. The up regulation of Na^+/K^+ -ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrylate. *J Affect Disord* 1995; 34(1): 33-9. [PMID: 7622737]
60. Buckley CD, Aronson JK. Prolonged half-life of verapamil in a case of overdose: implications for therapy. *Br J Clin Pharmacol* 1995; 39: 680-3. [PMID: 7654488]
61. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJM, Aronson JK, Grahame-Smith DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. *Br J Clin Pharmacol* 1996; 42(4): 423-9. [PMID: 8904613]
62. De Silva HA, Carver JG, Aronson JK. Effects of high external concentrations of K^+ on $^{86}\text{Rb}^+$ efflux in human platelets: evidence for $\text{Na}^+/\text{K}^+/\text{2Cl}^-$ co-transport. *Clin Sci (Lond)* 1996; 91(6): 725-31. [PMID: 8976808]
63. Farooqi IS, Aronson JK. Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. *Q J Med* 1996; 89(12): 953-5. [PMID: 9015489]
64. De Silva HA, Aronson JK. Evidence for an $\text{R}(+)$ -[(dihydroindenyl)oxy]alkanoic acid-sensitive K^+/Cl^- co-transporter in human platelets and its interaction with the $\text{Na}^+/\text{K}^+/\text{2Cl}^-$ co-transporter. *Clin Sci (Lond)* 1997; 93(3): 243-8. [PMID: 9337639]
65. De Silva HA, Carver JG, Aronson JK. Pharmacological evidence of calcium-activated and voltage-gated potassium channels in human platelets. *Clin Sci (Lond)* 1997; 93(3): 249-55. [PMID: 9337640]
66. De Silva HA, Aronson JK, Grahame-Smith DG, Jobst KA, Smith AD. Abnormal function of potassium channels in the platelets of patients with Alzheimer's disease. *Lancet* 1998; 352(9140): 1590-3. [PMID: 9843105]
67. Mendes Ribiero AC, Brunini TMC, Yaqoob M, Aronson JK, Mann GE, Ellory JC. Identification of system y^+L as the high affinity transporter for L-arginine in human platelets: upregulation of L-arginine influx in uraemia. *Pflügers Arch Eur J Pharmacol* 1999; 438(4): 573-5. [PMID: 10519154]
68. Aronson JK. "Where name and image meet"—the argument for "adrenaline" *BMJ* 2000; 320(7233): 506-9. [PMID: 10678871]
69. Nobel CSI, Aronson JK, van den Dobbelsteen DJ, Slater AFG. Inhibition of Na^+/K^+ -ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. *Apoptosis* 2000; 5(2): 153-63. [PMID: 11232243]
70. Haeseler G, Mamarvar M, Bufler J, Dengler R, Hecker H, Aronson JK, Piepenbrock S, Leuwer M. Voltage-dependent block of normal and mutant muscle sodium channels by benzylalcohol. *Br J Pharmacol* 2000; 130(6): 1321-30. [PMID: 10903972]
71. Haeseler G, Piepenbrink A, Bufler J, Dengler R, Hecker H, Aronson JK, Piepenbrock S, Leuwer M. Phenol derivatives accelerate inactivation kinetics in one inactivation-deficient mutant human skeletal muscle Na^+ channel. *Eur J Pharmacol* 2001; 416(1-2): 11-18. [PMID: 11282107]
72. Haeseler G, Piepenbrink A, Bufler J, Dengler R, Aronson JK, Piepenbrock S, Leuwer M. Structural requirements for voltage-dependent block of muscle sodium channels by phenol derivatives. *Br J Pharmacol* 2001; 132(8): 1916-24. [PMID: 11309264]
73. Derry S, Loke YK, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. *BMJ Med Res Methodol* 2001; 1: 7. <http://www.biomedcentral.com/1471-2288/1/7/> Epub 2001 Sep 3. [PMID: 11591220]
74. Aronson JK, Loke Y, Derry S. Adverse drug reactions: keeping up to date. *Fundam Clin Pharmacol* 2002; 16(1): 49-56. [PMID: 11903512]
75. Haeseler G, Bufler J, Merken S, Dengler R, Aronson JK, Leuwer M. Block of voltage-operated sodium channels by 2,6-dimethylphenol, a structural analogue of lidocaine's aromatic tail. *Br J Pharmacol* 2002; 137(2): 285-93. [PMID: 12208786]
76. de Silva HA, Fonseca MD, Pathmeswaran A, Alahakoon DGS, Ratnatilake GA, Gunatilake SB, Ranasingha CD, Laloo DG, Aronson JK, de Silva HJ. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomized, placebo-controlled trial. *Lancet* 2003; 361(9373): 1935-8. [PMID: 12801736]

77. Aronson JK, Ferner RE. Joining the DoTS. New approach to classifying adverse drug reactions. *BMJ* 2003; 327(7425): 1222-5. [PMID: 14630763]
78. Maxwell S, Walley T; BPS Clinical Section Committee. Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow's doctors. *Br J Clin Pharmacol* 2003; 55(6): 496-503. [PMID: 12814441]
79. Leuwer M, Haeseler G, Hecker H, Bufler J, Dengler R, Aronson JK. An improved model for the binding of lidocaine and structurally related local anaesthetics to fast-inactivated voltage-operated sodium channels, showing evidence of cooperativity. *Br J Pharmacol* 2004; 141(1): 47-54. [PMID: 14662728]
80. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. *Br J Clin Pharmacol* 2004; 57(5): 616-21. [PMID: 15089815]
81. Ferner RE, Aronson JK. National differences in publishing reports of adverse drug reactions. *Br J Clin Pharmacol* 2005; 59(1): 108-11. [PMID: 15606448]
82. Aronson JK. Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. *J Eval Clin Pract* 2005; 11(2): 195-208. [PMID: 15813716]
83. Haeseler G, Ahrens J, Kampfl K, Bufler J, Dengler R, Hecker H, Aronson JK, Leuwer M. Structural features of phenol derivatives determining potency for activation of chloride currents via $\alpha(1)$ homomeric and $\alpha(1)\beta$ heteromeric glycine receptors. *Br J Pharmacol* 2005; 145(7): 916-25. [PMID: 15912136]
84. Aronson JK, Ferner RE. Clarification of terminology in drug safety. *Drug Saf* 2005; 28(10): 851-70. [PMID: 16180936]
85. Loke YK, Derry S, Price D, Aronson JK. Case reports of suspected adverse drug reactions—systematic literature survey of follow-up. *BMJ* 2006; 332(7537): 335-9. Epub 2006 Jan 18. [PMID: 16421149]
86. Ferner RE, Aronson JK. Communicating information about drug safety. *BMJ* 2006; 333(7559): 143-5. [PMID: 16840480]
87. Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. *Drug Saf* 2006; 29(11): 1011-22. [PMID: 17061907]
88. Aronson JK, Hauben M. Anecdotes that provide definitive evidence. *BMJ* 2006; 332(7581): 1267-9. [PMID: 17170419]
89. Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high grade ore. *Drug Saf* 2007; 30(8): 645-55. [PMID: 17696577]
90. Loke YK, Price D, Herxheimer A; the Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. *BMJ Med Res Methodol* 2007; 7: 32. [PMID: 17615054]
91. Lechler R, Paice E, Hays R, Petty-Saphon K, Aronson JK, Bramble M, Hughes I, Rigby E, Anwar Q, Webb D, Maxwell S, Martin J, Maskrey N, Walker S. Outcomes of the Medical Schools Council Safe Prescribing Working Group. 2007. <http://www.medschools.ac.uk/News/Pages/Safe-Prescribing-Working-Group.aspx>.
92. Aronson JK, Price D, Ferner RE. A strategy for regulatory action when new adverse effects of a licensed product emerge. *Drug Saf* 2009; 32(2): 91-8. doi: 10.2165/00002018-200932020-00002. [PMID: 19236116]
93. Hauben M, Aronson JK. Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. *Drug Saf* 2009; 32(2): 99-110. doi: 10.2165/00002018-200932020-00003. [PMID: 19236117]
94. Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? *J R Soc Med* 2009; 102(5): 186-94. [PMID: 19417051]
95. Members of EMERGE, the Erice Medication Errors Research Group; Agrawal A, Aronson JK, Britten N, Ferner RE, de Smet PA, Fialová D, Fitzgerald RJ, Likić R, Maxwell SR, Meyboom RH, Minuz P, Onder G, Schachter M, Velo G. Medication errors: problems and recommendations from a consensus meeting. *Br J Clin Pharmacol* 2009; 67(6): 592-8. [PMID: 19594525]
96. Barkun JS, Aronson JK, Feldman LS, Maddern GJ, Strasberg SM; Balliol Collaboration, Altman DG, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Flum DR, Glasziou P, Marshall JC, McCulloch P, Nicholl J, Reeves BC, Seiler CM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Evaluation and stages of surgical innovations. *Lancet* 2009; 374(9695): 1089-96. [PMID: 19782874]
97. Ergina PL, Cook JA, Blazeby JM, Boutron I, Clavien PA, Reeves BC, Seiler CM; Balliol Collaboration, Altman DG, Aronson JK, Barkun JS, Campbell WB, Cook JA, Feldman LS, Flum DR, Glasziou P, Maddern GJ, Marshall JC, McCulloch P, Nicholl J, Strasberg SM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Grant A, Gray M, Greenhalgh

- R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. Challenges in evaluating surgical innovation. *Lancet* 2009; 374(9695): 1097-104. [PMID: 19782876]
98. McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P, Marshall JC, Nicholl J; Balliol Collaboration, Aronson JK, Barkun JS, Blazeby JM, Boutron IC, Campbell WB, Clavien PA, Cook JA, Ergina PL, Feldman LS, Flum DR, Maddern GJ, Nicholl J, Reeves BC, Seiler CM, Strasberg SM, Meakins JL, Ashby D, Black N, Bunker J, Burton M, Campbell M, Chalkidou K, Chalmers I, de Leval M, Deeks J, Ergina PL, Grant A, Gray M, Greenhalgh R, Jenicek M, Kehoe S, Lilford R, Littlejohns P, Loke Y, Madhock R, McPherson K, Meakins J, Rothwell P, Summerskill B, Taggart D, Tekkis P, Thompson M, Treasure T, Trohler U, Vandenbroucke J. No surgical innovation without evaluation: the IDEAL recommendations. *Lancet* 2009; 374(9695): 1105-12. [PMID: 19782875]
 99. Hughes DA, Aronson JK. A systematic review and empirical analysis of the relation between dose and duration of drug action. *J Clin Pharmacol* 2010; 50(1): 17-26. Epub 2009 Oct 1. [PMID: 19797537]
 100. Ferner RE, Aronson JK. EIDOS: A mechanistic classification of adverse drug effects. *Drug Saf* 2010; 33(1): 15-23. doi: 10.2165/11318910-000000000-00000. [PMID: 20000863]
 101. Ferner RE, Hughes DA, Aronson JK. NICE and new: appraising innovation. *BMJ* 2010; 340: b5493. doi: 10.1136/bmj.b5493. [PMID: 20051468]
 102. Aronson JK. A manifesto for clinical pharmacology from principles to practice. *Br J Clin Pharmacol* 2010; 70(1): 3-13. [PMID: 20642541]
 103. Ferner RE, Aronson JK. Preventability of drug-related harms. Part 1: A systematic review. *Drug Saf* 2010; 33(11): 985-94. doi: 10.2165/11538270-000000000-00000. [PMID: 20925436]
 104. Aronson JK, Ferner RE. Preventability of drug-related harms. Part 2: Proposed criteria, based on frameworks that classify adverse drug reactions. *Drug Saf* 2010; 33(11): 995-1002. doi: 10.2165/11538280-000000000-00000. [PMID: 20925437]
 105. Howick J, Glasziou P, Aronson JK. Evidence-based mechanistic reasoning. *J R Soc Med* 2010; 103(11): 433-41. [PMID: 21037334]
 106. Aronson JK. How to attract, retain, and nurture young academic clinicians: lessons from Peter B Medawar and James D Watson. *J R Soc Med* 2011; 104(1): 6-14. [PMID: 21205772]
 107. Buclin T, Telenti A, Perera R, Csajka C, Furrer H, Aronson JK, Glasziou P. Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy. *PLoS One* 2011; 6(4): e18578. [PMID: 21494630]
 108. De Silva HA, Pathmeswaran A, Ranasinha CD, Jayamanne S, Samarakoon SB, Hittharage A, Kalupahana R, Ratnatilaka GA, Uluwathage W, Aronson JK, Armitage JM, Lalloo DG, De Silva HJ. Low-dose adrenaline, promethazine and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. *PLoS Med* 2011; 8(5): e1000435. Epub 2011 May 10. [PMID: 21572992]
 109. Aronson JK. What do clinical pharmacologists do? A questionnaire survey of senior UK clinical pharmacologists. *Br J Clin Pharmacol* 2012; 73(2): 161-9. Epub 2011 Aug 10. doi: 10.1111/j.1365-2125.2011.04079.x [PMID: 21831197]
 110. Barker CI, Talbot JCC, Aronson JK. Selected national pharmacovigilance websites. A analysis of contents. *Drug Saf* 2012; 35(2): 141-8. doi: 10.2165/11596270-000000000-00000. [PMID: 22168572]
 111. Smith SW, Hauben M, Aronson JK. Paradoxical and bidirectional drug effects. *Drug Saf* 2012; 35(3): 173-89. doi: 10.2165/11597710-000000000-00000. [PMID: 22272687]
 112. Aronson JK, Hauben M, Bate A. Defining "surveillance" in drug safety. *Drug Saf* 2012; 35(5): 1-11. [PMID: 22462653]
 113. Aronson JK, Ferner RE, Hughes DA. Defining rewardable innovation in drug therapy. *Nat Rev Drug Discov* 2012; 11(4): 253-4. doi: 10.1038/nrd3715. [PMID: 22460109]
 114. Vrijens B, De Geest S, Hughes D, Kardas P, Demonceau J, Ruppar T, Dobbels F, Fargher E, Morrison V, Lewek P, Matyjaszczyk M, Mshelia C, Lyne W, Aronson JK, Urquhart J; ABC project team. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol* 2012; 73(5): 691-705. doi: 10.1111/j.1365-2125.2011.04167.x. [PMID: 22486599]
 115. McDowell SE, Thomas SK, Coleman JJ, Aronson JK, Ferner RE. A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy. *J R Soc Med* 2012; in press.
 116. Howick J, Glasziou P, Aronson JK. Problems with using mechanisms to bridge the gap between controlled clinical trials and 'target' populations. *Theor Med Bioeth* 2013; in press.
 117. Aronson JK. Distinguishing hazards and harms, adverse drug effects and adverse drug reactions: implications for clinical trials, biomarkers, monitoring, and surveillance. *Drug Saf* 2013; in press.
 118. Howick J, Glasziou P, Aronson JK. Consideration of mechanisms in solving the problem of applying study results to target populations. Submitted.
 119. Aresti N, Aronson J, Ramachandran M. Non-Original Malappropiate Eponymous Nomenclature (NOMEN): examples relevant to paediatric orthopaedics. Submitted.

120. Iessa N, Star K, Murray ML, Wilton L, Curran S, Edwards R, Aronson JK, Besag F, Wong ICK. Increased reporting of suicides associated with use of mirtazapine following publicity fails to add evidence of a true association. Submitted.
121. Floor-Schreuder A, Geerts A FJ, Bouvy M L, Ferner R E, Aronson J K, De Smet PAGM. Towards improved drug-drug interaction management guidelines. Part I: Literature review and preliminary guideline items. Submitted.
122. Floor-Schreuder A, Geerts A FJ, Bouvy M L, Ferner R E, Aronson J K, De Smet PAGM. Towards improved drug-drug interaction management guidelines. Part II: Development of MAGIC (Model for Assessment of Guidelines on Interacting Compounds). Submitted.
123. Taylor K S, Heneghan C J, Farmer A J, Fuller A M, Adler A I, Aronson J K, Stevens R J. All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large UK primary care database. Submitted.

B Books and edited journal issues

1. Grahame-Smith D G, Aronson J K. The Oxford Textbook of Clinical Pharmacology and Drug Therapy. Oxford University Press, 1984. ISBN 0-19-261172-0 (paperback); 0-19-261492-4 (cased); 0-19-442426-X (paperback ELBS edition).
2. Dukes MNG, editor, Aronson J K, Blackwell B, Elis J, Folb P I, Hoigné R, Hvidberg EF, Lunde PKM, Tester-Dalderup C B M, von Eickstedt K -W, Westerholm B, co-editors. Meyler's Side Effects of Drugs. 10th edition. Amsterdam: Elsevier, 1984. ISBN 0-444-90323-2.
3. Aronson J K. An Account of The Foxglove and its Medical Uses 1785-1985. Oxford: Oxford University Press, 1985 [incorporating a facsimile of William Withering's monograph 'An account of the foxglove ' (1785) in a specially annotated edition]. ISBN 0-19-261501-7. [Spanish translation by D Mario Petit Guinovart & Juan Hernández Herrero, 1988.]
4. Dukes MNG, editor, Aronson J K, Blackwell B, Dittmann S, Folb P I, Hoigné R, Hvidberg EF, Tester-Dalderup C B M, Tognoni G, von Eickstedt K -W, Westerholm B, co-editors. Meyler's Side Effects of Drugs. 11th edition. Amsterdam: Elsevier, 1988. ISBN 0-444-90484-0.
5. Dukes MNG, Aronson J K, editors. Side Effects of Drugs, Annual 15. Amsterdam: Elsevier, 1991. ISSN 0378-6080.
6. Grahame-Smith D G, Aronson J K. The Oxford Textbook of Clinical Pharmacology and Drug Therapy. Second edition. Oxford: Oxford University Press, 1992. ISBN 0-19-261676-5 (hardback); 0-19-261675-7 (paperback).
7. Dukes MNG, editor, Aronson J K, Blackwell B, Dittmann S, Folb P I, Hoigné R, Hvidberg EF, Tester-Dalderup C B M, Tognoni G, von Eickstedt K -W, Westerholm B, co-editors. Meyler's Side Effects of Drugs. 12th edition. Amsterdam: Elsevier, 1992. ISBN 0-444-89524-8.
8. Dukes MNG, Aronson J K, editors. Side Effects of Drugs, Annual 16. Amsterdam: Elsevier, 1992. ISBN 0-444-89657-0. ISSN 0378-6080.
9. Aronson J K, Hardman M, Reynolds D J M. ABC of Monitoring Drug Therapy. London: BMJ Publishing Group, 1993. ISBN 0-727-907913.
10. Aronson J K, Van Boxtel C J, editors. Side Effects of Drugs, Annual 17. Amsterdam: Elsevier, 1993. ISBN 0-444-82005-1. ISSN 0378-6080.
11. Aronson J K, Van Boxtel C J, editors. Side Effects of Drugs, Annual 18. Amsterdam: Elsevier, 1994. ISBN 0-444-81939-8. ISSN 0378-6080.
12. Aronson J K, Van Boxtel C J, editors. Side Effects of Drugs, Annual 19. Amsterdam: Elsevier, 1996. ISBN 0-444-82531-2. ISSN 0378-6080.
13. Dukes MNG, editor, Aronson J K, Folb P I, Hoigné R, Lunde PKM, Tester-Dalderup C B M, Van Boxtel C J, Vrhovac B, co-editors. Meyler's Side Effects of Drugs. 13th edition. Amsterdam: Elsevier, 1996. ISBN 0-444-82405-7.
14. Aronson J K, editor. Side Effects of Drugs, Annual 20. Amsterdam: Elsevier, 1997. ISBN 0-444-82532-0. ISSN 0378-6080.
15. Aronson J K, editor. Side Effects of Drugs, Annual 21. Amsterdam: Elsevier, 1998. ISBN 0-444-82818-4. ISSN 0378-6080.
16. Aronson J K, editor. Side Effects of Drugs, Annual 22. Amsterdam: Elsevier, 1999. ISBN 0-444-50092-8. ISSN 0378-6080.
17. Aronson J K, editor. Side Effects of Drugs, Annual 23. Amsterdam: Elsevier, 2000. ISBN 0-444-50212-2. ISSN 0378-6080.
18. Dukes MNG, Aronson J K, editors. Meyler's Side Effects of Drugs. An Encyclopedia of Adverse Reactions and Interactions. 14th edition. Amsterdam: Elsevier, 2000. ISBN 0-444-50993-6.
19. Aronson J K, editor. Side Effects of Drugs, Annual 24. Amsterdam: Elsevier, 2001. ISBN 0-444-50512-1. ISSN 0378-6080.

20. Grahame-Smith DG, Aronson JK. The Oxford Textbook of Clinical Pharmacology and Drug Therapy. Third edition. Oxford: Oxford University Press, 2002. ISBN 0-19-850944-8 (hardback); 0-19-263234-5 (paperback).
21. Aronson JK, editor. Side Effects of Drugs, Annual 25. Amsterdam: Elsevier, 2002. ISBN 0-444-50674-8. ISSN 0378-6080.
22. Aronson JK, editor. Side Effects of Drugs, Annual 26. Amsterdam: Elsevier, 2003. ISBN 0-444-50999-2. ISSN 0378-6080.
23. Aronson JK, editor. Side Effects of Drugs, Annual 27. Amsterdam: Elsevier, 2004. ISBN 0-444-51356-6. ISSN 0378-6080.
24. Cuervo LG, Aronson JK editors. BMJ special issue: "Balancing benefits and harms in health care", 3 July 2004.
25. Aronson JK editor. British Journal of Clinical Pharmacology special issue: "Citation Classics in the British Journal of Clinical Pharmacology, 1974-2003", December 2004.
26. Richards DB, Aronson JK. The Oxford Handbook of Practical Drug Therapy. Oxford: Oxford University Press, 2005. ISBN 0-19-853007-2.
27. Aronson JK, editor. Side Effects of Drugs, Annual 28. Amsterdam: Elsevier, 2005. ISBN 0-444-51571-2. ISSN 0378-6080.
28. Aronson JK editor. British Journal of Clinical Pharmacology special issue: "Clinical Pharmacology: Past, Present, and Future", June 2006.
29. Aronson JK, editor. Meyler's Side Effects of Drugs—The International Encyclopedia of Adverse Drug Reactions and Interactions, 15th edition (6 volumes). Amsterdam: Elsevier, 2006. ISBN 978-044-50998-7.
30. Aronson JK editor. British Journal of Clinical Pharmacology special issue: "Adverse Drug Reactions", February 2007.
31. Aronson JK, editor. Side Effects of Drugs, Annual 29. Amsterdam: Elsevier, 2007. ISBN 978-0-444-51986-3. ISSN 0378-6080.
32. Glasziou P, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell Publishing/BMJ Books, 2008. ISBN 978-1-4051-5399-7.
33. Aronson JK, editor. Side Effects of Drugs, Annual 30. Amsterdam: Elsevier, 2008. ISBN 978-0-444-52767-7. ISSN 0378-6080.
34. Aronson JK, editor. Meyler's Side Effects of Herbal Medicines. Amsterdam: Elsevier, 2008. ISBN 978-044-453269-5.
35. Aronson JK, editor. Meyler's Side Effects of Psychiatric Drugs. Amsterdam: Elsevier, 2008. ISBN 978-044-453266-4.
36. Aronson JK, editor. Meyler's Side Effects of Drugs Used in Anesthesia. Amsterdam: Elsevier, 2008. ISBN 978-044-453270-1.
37. Aronson JK, editor. Meyler's Side Effects of Cardiovascular Drugs. Amsterdam: Elsevier, 2008. ISBN 978-044-453268-8.
38. Aronson JK, editor. Meyler's Side Effects of Endocrine and Metabolic Drugs. Amsterdam: Elsevier, 2008. ISBN 978-044-453271-8.
39. Aronson JK editor. British Journal of Clinical Pharmacology special issue: "Medication Errors", June 2009.
40. Aronson JK, editor. CME: Clinical pharmacology. Clinical Medicine 2009; 9(5): 478-97.
41. Aronson JK, editor. Side Effects of Drugs, Annual 31. Amsterdam: Elsevier, 2009. ISBN 978-0-444-53294-7. ISSN 0378-6080.
42. Aronson JK, editor. Meyler's Side Effects of Antimicrobial Drugs. Amsterdam: Elsevier, 2010. ISBN 978-044-453272-5.
43. Aronson JK, editor. Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Amsterdam: Elsevier, 2010. ISBN 978-044-453273-2.
44. Aronson JK, editor. Meyler's Side Effects of Drugs in Cancer and Immunology. Amsterdam: Elsevier, 2010. ISBN 978-044-453267-1.
45. Ramachandran M, Aronson JK. Doctoring History. London: Royal Society of Medicine, 2010. ISBN 978-1-85315-812-4.
46. Aronson JK, editor. Side Effects of Drugs, Annual 32. Amsterdam: Elsevier, 2010. ISBN 978-0-444-53550-4. ISSN 0378-6080.
47. Talbot J, Aronson JK, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell, 2011. ISBN 978-0-470-98634-9 (cloth); 978-0-470-97504-6 (e-PDF).
48. Richards DB, Coleman JJ, Reynolds DJM, Aronson JK. The Oxford Handbook of Practical Drug Therapy. Oxford: Oxford University Press, 2nd edition, 2011. ISBN 978-0-19-956285-5.
49. Aronson JK, editor. Side Effects of Drugs, Annual 33. Amsterdam: Elsevier, 2011. ISBN 978-0-444-53741-6. ISSN 0378-6080.

50. Aronson JK editor. Special issue: “An Agenda for UK Clinical Pharmacology”, British Journal of Clinical Pharmacology 2012; 73(6): 843-5 and 861-982.
51. Aronson JK, editor. Side Effects of Drugs, Annual 34. Amsterdam: Elsevier, 2012; in press.

C Editorial reviews and commentaries—General

1. Anonymous [Aronson JK, Grahame-Smith DG]. Foxglove saga (continued). Lancet 1976; 2(7982): 405. [PMID: 73859]
2. Aronson JK. Digitalis intoxication. Clin Sci (Lond) 1983; 64(3): 253-8. [PMID: 6337012]
3. Aronson JK. Cardiac arrhythmias—theory and practice. Br Med J (Clin Res Ed) 1985; 290(6467): 487-8. [PMID: 3918643]
4. Boon NA, Aronson JK. Dietary salt and hypertension—treatment and prevention. Br Med J (Clin Res Ed) 1985; 290(6473): 949-50. [PMID: 3919863]
5. Aronson JK, Sear JW. Transdermal hyoscine (scopolamine) and postoperative vomiting. Anaesthesia 1986; 41(1): 1-3. [PMID: 3946769]
6. Aronson JK. Glycosides of plants and men. Med J Aust 1986; 144(10): 505-6. [PMID: 3713562]
7. Anonymous [Aronson JK]. Administration of drugs by the buccal route. Lancet 1987; 1(8534): 666-7. [PMID: 2882088]
8. Anonymous [Aronson JK]. Bepridil. Lancet 1988; 1(8580): 278-9. [PMID: 2893088]
9. Aronson JK, Dengler HJ, Dettli L, Follath F. Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 1988; 35(1): 1-7. [PMID: 3220089]
10. Aronson JK. Methods for expressing the characteristics of transmembrane ion transport systems. Clin Sci (Lond) 1990; 78(3): 247-54. [PMID: 1690620]
11. Aronson JK, Ng LL. HMG CoA reductase inhibitors in the treatment of hypercholesterolaemias. Q J Med 1990; 74(274): 111-15. [PMID: 2111916]
12. Smith AJ, Aronson JK, Thomas M. Antibiotics policies in the developing world. Eur J Clin Pharmacol 1991; 41(2): 85-7. [PMID: 1743251]
13. Ferner RE, Aronson JK. Errors in prescribing, preparing, and giving medicines—definition, classification, and prevention. In: Aronson JK, editor. Side Effects of Drugs, Annual 22. Amsterdam: Elsevier, 1999: xxiii-xxvi.
14. Ferner RE, Aronson JK. Medication errors, worse than a crime. Lancet 2000; 355(9208): 947-8. [PMID: 10768430]
15. Aronson JK. Forbidden fruit. Nat Med 2001; 7(1): 29-30. [PMID: 11135611]
16. Aronson JK. Anecdotes as evidence. BMJ 2003; 326(7403): 1346. [PMID: 12816800]
17. Aronson JK. PHARMA: Publishing Histories of Adverse Reactions to Medicaments Anecdotally. Reporting suspected adverse drug reactions and interactions: proposed guidelines for authors. <http://bmj.com/cgi/content/full/326/7403/1346/DC1#p>.
18. Aronson JK. Being wholistic. Focus Altern Complement Ther 2003; 8: 381-2.
19. Aronson JK. Live long and prosper: a mass strategy for treating the factors associated with ischaemic heart disease and stroke. J Med Screen 2004; 11(1): 1-2. [PMID: 15006105]
20. Cuervo LG, Aronson JK. The road to health care. BMJ 2004; 329(7456): 1-2. [PMID: 15231586]
21. Aronson JK. Open access publishing: too much oxygen? BMJ 2005; 330(7494): 759. [PMID: 15802718]
22. Aronson JK. Classifying adverse drug reactions in the 21st century. In: Aronson JK, editor. Side Effects of Drugs, Annual 28. Amsterdam: Elsevier, 2005: xxvii-xxxiii.
23. Aronson JK. “Open-access” publishing: first the evidence—then the verdict. J R Soc Med 2006; 99(3): 103-4. [PMID: 16508041]
24. Aronson JK. Commentary on: Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005; 142(12 Pt 2): 1090-9. The Cochrane Collaboration Methods Groups Newsletter 2006; 10: 8.
25. Aronson JK. Polypharmacy, appropriate and inappropriate. Br J Gen Pract 2006; 56(528): 484-5. [PMID: 16834872]
26. Aronson JK, Henderson G, Webb DJ, Rawlins MD. A prescription for better prescribing. BMJ 2006; 333(7566): 459-60. [PMID: 16946321]
27. Mehta DK, Aronson JK. Give a drug a good name. Lancet 2007; 369(9570): 1326-8. [PMID: 17448803]
28. Aronson JK. Something new every day. Defining innovation and innovativeness in drug therapy. J Ambulatory Care Manage 2008; 31(1): 65-8. [PMID: 18162799]
29. Aronson JK. PHARMA: Publishing Histories of Adverse Reactions to Medicaments Anecdotally. The PHARMA guidelines for reporting suspected adverse drug reactions. Drug Saf 2008; 31(4): 355-6 [PMID: 18366246].
30. Aronson JK. Changing beta-blockers in heart failure: when is a class not a class? Br J Gen Pract 2008; 58(551): 387-9. [PMID: 18505613].

31. Aronson JK. Gli errori nell'uso dei farmaci. *Focus Farmacovigilanza* 2008; 53: 1.
32. Aronson JK. Drug withdrawals because of adverse effects. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 30. Amsterdam: Elsevier, 2008: xxxi-xxxv.
33. Aronson JK. From prescription-only to over-the-counter medicines ('PoM to P'): time for an intermediate category. *Br Med Bull* 2009; 90: 63-9. Epub 2009 May 3. [PMID: 19414447]
34. Aronson JK. Reducing the frequency of medication errors. *EJHP Pract* 2010; 16(4): 61-3.
35. Aronson JK. Reducing prescribing errors through medical education. *Prescriber* 2011; 22(8): 6-7.
36. Aronson JK. Drug interactions—don't forget herbs, food, and devices. *RIPER PDIC Bull* 2011; 2(16): 7-9.

D Editorial commentaries—British Journal of Clinical Pharmacology

1. Aronson J K. Features of this month's *Journal*. [Preventing heart attacks and strokes; complementary medicines; genetic testing.] *Br J Clin Pharmacol* 2003; 55(3): 223-4. [PMCID: PMC1884223]
2. Aronson J K. Features of this month's *Journal*. [Managing reversible airways obstruction.] *Br J Clin Pharmacol* 2003; 55(4): 327-8. [PMCID: PMC1884239]
3. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ. *The British Journal of Clinical Pharmacology* Editors' Report for 2002. *Br J Clin Pharmacol* 2003; 55(4): 329-30. [PMCID: PMC1884226]
4. Aronson J K. Features of this month's *Journal*. [Teaching drug therapy; adverse effects of selective serotonin reuptake inhibitors; drug-induced QT interval prolongation; Chronopharmacology.] *Br J Clin Pharmacol* 2003; 55(6): 493-4. [PMCID: PMC1884267]
5. Aronson JK. Features of this month's *Journal*. [Uses of population pharmacokinetics; P glycoprotein and cardiac glycosides; pharmacokinetics.] *Br J Clin Pharmacol* 2003; 56(1): 1-2. [PMCID: PMC1884323]
6. Aronson JK. Features of this month's *Journal*. [Sex and the palpitating heart; age and sedation; ethnicity and blood pressure; ethnicity and cardiovascular disease.] *Br J Clin Pharmacol* 2003; 56(2): 141-2. [PMCID: PMC1884275]
7. Aronson J K. Features of this month's *Journal*. [Old-age medicine; New Age medicine; age and testosterone.] *Br J Clin Pharmacol* 2003; 56(3): 247-8. [PMCID: PMC1884352]
8. Aronson JK. Features of this month's *Journal*. [Keeping up to date; Predicting in vivo events from in vitro studies; Grapes and grapes; Serotonin syndrome in interactions with moclobemide.] *Br J Clin Pharmacol* 2003; 56(4): 347-8. [PMCID: PMC1884370]
9. Aronson J K. Features of this month's *Journal*. [Water under the bridge; Homoeopathy—proving or disproving? One for a man, two for a horse, but how much for a child? *Br J Clin Pharmacol* 2003; 56(5): 475-6. [PMCID: PMC1884404]
10. Aronson JK. Nurse prescribers and reporters. *Br J Clin Pharmacol* 2003; 56(6): 585-7. [PMID: 14616417]
11. Aronson JK. On being 30. *Br J Clin Pharmacol* 2004; 57(1): 1-5. [PMCID: PMC1884412]
12. Aronson JK. In defence of polypharmacy. *Br J Clin Pharmacol* 2004; 57(2): 119-20. [PMID: 14748809]
13. Aronson J K. Rational prescribing, a appropriate prescribing. *Br J Clin Pharmacol* 2004; 57(3): 229-30. [PMID: 14998417]
14. Aronson J K. Drug interactions—information, education, and the *British National Formulary*. *Br J Clin Pharmacol* 2004; 57(4): 371-2. [PMID: 15025733]
15. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ. *The British Journal of Clinical Pharmacology* Editors' Report for 2003. *Br J Clin Pharmacol* 2004; 57(5): 538-9. [PMCID: PMC1884489]
16. Aronson J K. On the waterfront—the breadth and depth of clinical pharmacology. *Br J Clin Pharmacol* 2004; 57(6): 693-4. [PMCID: PMC1884528]
17. Aronson JK. What is a clinical trial? *Br J Clin Pharmacol* 2004; 58(1): 1-3. [PMID: 15206985]
18. Aronson JK. Littluns and biguns. *Br J Clin Pharmacol* 2004; 58(2): 117-18. [PMID: 15255793]
19. Aronson JK. Over-the-counter medicines. *Br J Clin Pharmacol* 2004; 58(3): 231-4. [PMID: 15327581]
20. Aronson JK. Classifying drug interactions. *Br J Clin Pharmacol* 2004; 58(4): 343-4. [PMID: 15373925]
21. Baber NS, Ritter JM, Aronson JK. Medicines regulation and clinical pharmacology. *Br J Clin Pharmacol* 2004; 58(6): 569-70.
22. Aronson J K. Citation classics in the British Journal of Clinical Pharmacology, 1974–2003. *Br J Clin Pharmacol* 2004; 58(7): S699-702. [PMID: 15595958]
23. Aronson JK, Whelan E. Internationality. *Br J Clin Pharmacol* 2005; 59(1): 1-4. [PMID: 15606433]
24. Aronson JK. Write on. *Br J Clin Pharmacol* 2005; 59(2): 141-2. [PMID: 15676034]
25. Aronson JK. Moving about. *Br J Clin Pharmacol* 2005; 59(3): 263-4. [PMID: 15752370]
26. Aronson JK. Drug development: more science, more education. *Br J Clin Pharmacol* 2005; 59(4): 377-8. [PMID: 15801930]
27. Aronson J K. Biomarkers and surrogate endpoints. *Br J Clin Pharmacol* 2005; 59(5): 491-4. [PMID: 15842546]
28. Aronson JK, Lennard MS, Ritter JM, Begg EJ, Baber NS. Editors' report 2004. *Br J Clin Pharmacol* 2005; 60(1): 5-6.

29. Aronson JK. Metameta-analysis. *Br J Clin Pharmacol* 2005; 60(2): 117-19. [PMID: 16042663]
30. Aronson JK. Monitoring therapy. *Br J Clin Pharmacol* 2005; 60(3): 229-30. [PMID: 16120059]
31. Aronson JK. One hundred years of a trial fibrillation. *Br J Clin Pharmacol* 2005; 60(4): 345-6. [PMID: 16187965]
32. Aronson JK. Prescribing statins. *Br J Clin Pharmacol* 2005; 60(5): 457-8. [PMID: 16236034]
33. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ, Lewis LD. Today's science, tomorrow's medicines. *Br J Clin Pharmacol* 2006; 61(1): 1-4. [PMID: 16390345]
34. Aronson JK. Medicines and the media. *Br J Clin Pharmacol* 2006; 61(2): 121-2. [PMID: 16433865]
35. Aronson JK. Rare diseases and orphan drugs. *Br J Clin Pharmacol* 2006; 61(3): 243-5. [PMID: 16487216]
36. Aronson JK. Monitoring for harms of therapy. *Br J Clin Pharmacol* 2006; 61(4): 365-6. [PMID: 16542195]
37. Aronson JK. A prescription for better prescribing. *Br J Clin Pharmacol* 2006; 61(5): 487-91. [PMID: 16669839]
38. Aronson JK, Lennard MS, Ritter JM, Baber NS, Begg EJ, Lewis LD. Editors' report 2005. *Br J Clin Pharmacol* 2006; 61(5): 492-3. [PMCID: PMC1885061]
39. Aronson JK. Clinical pharmacology: past, present, and future. *Br J Clin Pharmacol* 2006; 61(6): 647-9. [PMID: 16722824]
40. Aronson JK. Risk perception in drug therapy. *Br J Clin Pharmacol* 2006; 62(2): 135-7. [PMID: 16842386]
41. Aronson JK. The NSAID roller coaster: more about rofecoxib. *Br J Clin Pharmacol* 2006; 62(3): 257-9. [PMID: 16934039]
42. Aronson JK. Balanced prescribing. *Br J Clin Pharmacol* 2006; 62(6): 629-32. [PMID: 17118122]
43. Aronson JK, Lennard MS, Ritter JM, Begg EJ, Lewis LD, Schachter M. Editors' review of 2006 and the BJCP prize. *Br J Clin Pharmacol* 2007; 63(1): 1-4. [PMID: 17229039]
44. Aronson JK. A diverse drug reactions—no farewell to harms. *Br J Clin Pharmacol* 2007; 63(2): 131-5. [PMID: 17274787]
45. Aronson JK. Concentration-effect and dose-response relations in clinical pharmacology. *Br J Clin Pharmacol* 2007; 63(3): 255-7. [PMID: 17311674]
46. Aronson JK. Compliance, concordance, adherence. *Br J Clin Pharmacol* 2007; 63(4): 383-4. [PMID: 17378797]
47. Aronson JK. Drug therapy in kidney disease. *Br J Clin Pharmacol* 2007; 63(5): 509-11. [PMID: 17488361]
48. Aronson JK. Communicating information about drug interactions. *Br J Clin Pharmacol* 2007; 63(6): 637-9. [PMCID: PMC2000589]
49. Aronson JK. An agenda for research on adverse drug reactions. *Br J Clin Pharmacol* 2007; 64(2): 119-21. [PMID: 17635504]
50. Aronson JK, Cohen A, Ritter JM, Begg EJ, Lewis LD, Schachter M. Editors' report 2006. *Br J Clin Pharmacol* 2007; 64(3): 253-4. [PMCID: PMC2000648]
51. Aronson JK. Plagiarism—please don't copy. *Br J Clin Pharmacol* 2007; 64(4): 403-5. [PMID: 17880356]
52. Aronson JK. Old drugs—new uses. *Br J Clin Pharmacol* 2007; 64(5): 563-5. [PMID: 17935601]
53. Aronson JK. Time to abandon the term 'patient concordance'. *Br J Clin Pharmacol* 2007; 64(5): 711-3. [PMCID: PMC2203277]
54. Aronson JK, Cohen A, Lewis LD. Review of 2007. Clinical pharmacology—providing tools and expertise for translational medicine. *Br J Clin Pharmacol* 2008; 65(2): 154-7. [PMID: 18251756]
55. Aronson JK. Medication errors—EMERGING solutions. *Br J Clin Pharmacol* 2009; 67(6): 589-91. [PMID: 19594524]
56. Aronson JK. Finding a VOICE for UK Clinical Pharmacology. *Br J Clin Pharmacol* 2012; 73(6): 843-5. doi: 10.1111/j.1365-2125.2012.04233.x. [PMID: 22360150]

E Book chapters and reviews

1. Aronson JK. The application of digoxin radioimmunoassay in monitoring drug therapy. In: Pasternak C, editor. *Radioimmunoassay in clinical biochemistry*. London: Heyden, 1975: 91-100.
2. Youdim MBH, Green AR, Aronson JK. The implications of the effects of iron deficiency on behaviour and drug metabolism. In: Pitcher CS, Richardson RG, editors. *Anaemia in general practice. The place of haematinics*. Abbott, 1977: 37-42.
3. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs, Annual 2*. Amsterdam: Excerpta Medica, 1978: Chapter 17A.
4. Grahame-Smith DG, Aronson JK. Assessment of digoxin action by a pharmacodynamic biochemical method. In: Bodem G, Dengler H, editors. *Cardiac glycosides*. Heidelberg: Springer-Verlag, 1978: 242-53.

5. Grahame-Smith DG, Aronson JK, Ford AR. The effect of digoxin on red blood cell function and its relationship to the therapeutic response. In: Tillement J, editor. *Advances in pharmacology and therapeutics*. Volume 7, Biochemical clinical pharmacology. Oxford: Pergamon Press, 1978: 15-22.
6. Aronson JK. An aide-memoire for the construction and assessment of clinical trials. *Oxf Med Sch Gaz* 1979; 31: 22-3.
7. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs*, Annual 3. Amsterdam: Excerpta Medica, 1979: Chapter 17A.
8. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs*, Annual 4. Amsterdam: Excerpta Medica, 1980: Chapter 18.
9. Aronson JK. Clinical pharmacokinetics of digoxin. *Clin Pharmacokin* 1980; 5(2): 137-49. [PMID: 6988136]
10. Aronson JK. Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' own tissues during glycoside therapy. In: Rietbrock N, Woodcock BG, Neuhaus G, editors. *Methods in clinical pharmacology*. Braunschweig/Wiesbaden: Vieweg, 1980: 17-25.
11. Aronson JK. The effects of digoxin on red cell digitalis receptor function in man. In: *Proceedings of the First World Conference on Clinical Pharmacology and Therapeutics*. London: Macmillan, 1980: 135-44.
12. Aronson JK, Grahame-Smith DG. Adverse drug interactions. *Br Med J (Clin Res Ed)* 1981; 282(6260): 288-91. [PMID: 6779990] [Reprinted in *Today's Treatment/4*, London: BMA, 1981.]
13. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs*, Annual 5. Amsterdam: Excerpta Medica, 1981: Chapter 18.
14. Aronson JK. Digoxin: clinical aspects. In: Richens A, Marks V, editors. *Therapeutic drug monitoring*. London and Edinburgh: Churchill Livingstone, 1981: Chapter 17A.
15. Aronson JK. Is digitalis useful in clinical practice? *Oxford Medical School Gazette* 1981; 32: 8-9.
16. Aronson JK. The interpretation of bradycardia in patients in digitalized patients. *Pract Cardiol* 1981; 7: 114-21.
17. Aronson JK, Ford AR, Grahame-Smith DG. Techniques for studying the pharmacodynamic effects of cardiac glycosides on patients' tissues during glycoside therapy. *Klin Wochenschr* 1981; 59(24): 1323-32. [PMID: 6275162]
18. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs*, Annual 6. Amsterdam: Excerpta Medica, 1982: Chapter 18.
19. Aronson JK. Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. *Clin Pharmacokin* 1983; 8(2): 155-78. [PMID: 6342898]
20. Aronson JK. Prevention and detection of adverse drug interactions. *Presc J* 1983; 23: 66-75.
21. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs*, Annual 7. Amsterdam: Excerpta Medica, 1983: Chapter 18.
22. Aronson JK. Indications for the measurement of plasma digoxin concentrations. *Drugs* 1983; 26(3): 230-42. [PMID: 6352238] [Reprinted in *New Ethicals* 1984; 21: 123-39.]
23. Green AR, Aronson JK. The pharmacokinetics of oral L-tryptophan: effects of dose and of concomitant pyridoxine, allopurinol or nicotinamide administration. In: Van Praag H, Mendlewicz J, editors. *Management of depression with monoamine precursors*. *Adv Biol Psychiatry* 1984; 10: 67-81.
24. Aronson JK. Digitalis. In: Sleight P, Jones JV, editors. *Scientific foundations of cardiology*. London: Heinemann, 1984: Chapter 64.
25. Aronson JK. Factors predisposing to digitalis toxicity. *Pract Cardiol* 1984; 10: 49-59.
26. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs*, Annual 8. Amsterdam: Elsevier, 1984: Chapter 18.
27. Aronson JK. Receptors and their relevance to drug therapy. *Med Int* 1984; 2: 281-5.
28. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Meyler's side effects of drugs*. 10th edition. Amsterdam: Elsevier, 1984: Chapter 18.
29. Aronson JK. Digitalis. In: Parnham MJ, Bruinvels J, editors. *Discoveries in pharmacology*. Amsterdam: Elsevier, 1984: Part 3, Chapter 3.
30. Aronson JK. The role of the Na⁺,K⁺-ATPase in the regulation of vascular smooth-muscle contractility, and its relationship to essential hypertension. *Trans Biochem Soc* 1984; 12(6): 943-5. [PMID: 6099292]
31. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. *Side Effects of Drugs*, Annual 9. Amsterdam: Elsevier, 1985: Chapter 18.
32. Aronson JK. Digoxin. *Contemp Issues Clin Biochem* 1985; 3: 182-210. [PMID: 3915966]
33. Aronson JK. Self-poisoning. In: Kennedy HJ, editor. *Emergencies in clinical medicine*. Oxford: Blackwell, 1985: Chapter 31.
34. Aronson JK. The clinical, haemodynamic, and pharmacological consequences of digoxin withdrawal after long-term treatment in patients with heart failure in sinus rhythm. In: Erdmann E, Greef KB, Skou JC, editors. *Cardiac glycosides 1785-1985*. Darmstadt: Steinkopff, 1986: 531-3.

35. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, editor. Side Effects of Drugs, Annual 10. Amsterdam: Elsevier, 1986: Chapter 18.
36. Hardman M, Aronson JK. Drugs for heart failure. Update 1986; 207-18.
37. Aronson JK. Pharmacological terms. Receptors, agonists and antagonists. Presc J 1986; 26: 163-5.
38. Aronson JK. Digitalis. In: Weatherall DJ, Ledingham JGG, Warrell D, editors. Oxford textbook of medicine. Oxford: Oxford University Press, 1987: 13.101-5.
39. Aronson JK. Digitalis intoxication and its treatment. Top Circ 1987; 2: 9-12.
40. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. Side Effects of Drugs, Annual 11. Amsterdam: Elsevier, 1987: Chapter 18.
41. Aronson JK. Interactions that matter: antiarrhythmic drugs. Presc J 1987; 27: 27-31.
42. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. Side Effects of Drugs, Annual 12. Amsterdam: Elsevier, 1988: Chapter 18.
43. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, editor. Meyler's side effects of drugs. 11th edition. Amsterdam: Elsevier, 1988: Chapter 18.
44. Aronson JK. Receptors and their relevance to drug therapy. Medicine 1988; 59: 2429-34. [Reprinted in Br J Pharm Pract 1989; 11: 372-8.]
45. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. Side Effects of Drugs, Annual 13. Amsterdam: Elsevier, 1989: Chapter 18.
46. Aronson JK. The treatment of self-poisoning. Emerg Med Serv 1989; 18: 51-60.
47. Aronson JK. Chronopharmacology: reflections on time and a new text. Lancet 1990; 335(8704): 1515-6.
48. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Beeley L, editors. Side Effects of Drugs, Annual 14. Amsterdam: Elsevier, 1990: Chapter 18.
49. Aronson JK. Routes of drug administration: 1. Rectal. Presc J 1991; 31: 91-7.
50. Aronson JK. Routes of drug administration: 2. Sublingual and buccal. Presc J 1991; 31: 169-74.
51. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Aronson JK, editors. Side Effects of Drugs, Annual 15. Amsterdam: Elsevier, 1991: Chapter 18.
52. Aronson JK. Potassium channels in nervous tissue. Biochem Pharmacol 1992; 43(1): 11-14. [PMID: 1734896]
53. Aronson JK. Routes of drug administration: 3. Dermal. Presc J 1992; 32: 35-40.
54. Aronson JK. Changes in the clinical pharmacology of drugs with age. In: Newman R, editor. Orthogeriatrics. London: Butterworth Heinemann, 1992: Chapter 4.
55. Aronson JK, Grahame-Smith DG. Adverse reactions to drugs. In: McGee JO'D, Isaacson PG, Wright NA, editors. Oxford textbook of pathology. Oxford: Oxford University Press, 1992. Volume 1, Chapter 10: 746-59.
56. Aronson JK. Pharmacokinetics for the prescriber. Med Int 1992; 101: 4221-8.
57. Reynolds DJM, Aronson JK. Selected side-effects: 8. Anaphylactoid reactions to intravenous vitamin K. Presc J 1992; 32: 167-70.
58. Aronson JK, Hardman M. ABC of monitoring drug therapy. Why monitor drug therapy? BMJ 1992; 305(6859): 947-8. [PMID: 1458079]
59. Aronson JK, Hardman M. ABC of monitoring drug therapy. Patient compliance. BMJ 1992; 305(6860): 1009-11. [PMID: 1458110]
60. Aronson JK, Hardman M. ABC of monitoring drug therapy. Measuring plasma drug concentrations. BMJ 1992; 305(6861): 1078-80. [PMID: 1467691]
61. Aronson JK, Hardman M. ABC of monitoring drug therapy. Digoxin. BMJ 1992; 305(6862): 1149-52. [PMID: 1463955]
62. Aronson JK, Hardman M, Reynolds DJM. ABC of monitoring drug therapy. Phenytoin. BMJ 1992; 305(6863): 1215-18. [PMID: 1467727]
63. Aronson JK, Reynolds DJM. ABC of monitoring drug therapy. Lithium. BMJ 1992; 305(6864): 1273-6. [PMID: 1477574]
64. Aronson JK, Hardman M, Reynolds DJM. ABC of monitoring drug therapy. Theophylline. BMJ 1992; 305(6865): 1355-8. [PMID: 1483087]
65. Aronson JK, Reynolds DJM. ABC of monitoring drug therapy. Aminoglycoside antibiotics. BMJ 1992; 305(6866): 1421-4. [PMID: 1486311]
66. Reynolds DJM, Aronson JK. ABC of monitoring drug therapy. Cyclosporin. BMJ 1992; 305(6867): 1491-4. [PMID: 1493401]
67. Aronson JK. The principles of prescribing in renal failure. Presc J 1992; 32: 220-31.
68. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, editor. Meyler's side effects of drugs. 12th edition. Amsterdam: Elsevier, 1992: Chapter 18.
69. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, Aronson JK, editors. Side Effects of Drugs, Annual 16. Amsterdam: Elsevier, 1992: Chapter 18.

70. Reynolds D JM, Aronson JK. A BC o f m onitoring d rug t herapy. M aking t he m ost o f p lasma d rug concentration measurements. *BMJ* 1993; 306(6869): 48-51. [PMID: 8435581]
71. Peto TEA, Aronson JK. Zidovudine. *Presc J* 1993; 32: 124-9.
72. Aronson JK. Drug absorption: achieving optimal clinical response. *Prescriber* 1993; 4(8): 77-80.
73. Aronson JK. Drug excretion: what the prescriber should know. *Prescriber* 1993; 4(16): 31-4.
74. Aronson JK. How drugs produce their pharmacological effects. *Prescriber* 1993; 4(19): 21-5.
75. Aronson JK. Drug action via enzymes and transport systems. *Prescriber* 1993; 4(20): 64-8.
76. Aronson JK. Routes of drug administration: 4. Inhalation. *Presc J* 1993; 32: 164-9.
77. Aronson JK. Serious drug interactions. *Practitioner* 1993; 237: 789-91. [PMID: 7903448]
78. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 17*. Amsterdam: Elsevier, 1993. Chapter 18.
79. Aronson JK. How the activity a nd num bers o f s odium/potassium p umps i n hum an l ymphocytes a re regulated. In: Haunsø S, Kjeldsen K, editors. *Proceedings of the XV European Section Meeting of the International Society for Heart Research*. Copenhagen. Bologna: Monduzzi Editore, 1994; 231-8.
80. Aronson JK. Beneficial drug interactions. *Practitioner* 1994; 238(1540): 514-8. [PMID: 7937504]
81. Aronson J K. A nti-infective d rugs. In: Walton J , B arondess J , L ock S , editors. *New O xford medical companion*. Oxford: OUP, 1994; 41-6.
82. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 18*. Amsterdam: Elsevier, 1995. Chapter 18.
83. Aronson JK. Local anesthetics. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 18*. Amsterdam: Elsevier, 1995. Chapter 12.
84. Aronson JK. Routes of drug administration: 5. Intramuscular. *Presc J* 1995; 35: 32-6.
85. Aronson JK, White N J. P rinciples o f cl inical p harmacology an d d rug t herapy. In: W eatherall D J, Ledingham JGG, Warrell D, editors. *Oxford textbook of medicine*, 3rd edition. Oxford: Oxford University Press, 1995: 1235-63.
86. Aronson JK. Confusion over similar drug names. Problems and solutions. *Drug Saf* 1995; 12(3): 155-60. [PMID: 7619327]
87. Aronson JK. How to choose an antibiotic. In: *The Medical Book*. London: Medilink Press, 1995/6: 37-8.
88. Aronson JK. Advantages and pitfalls of surrogate markers. In: Collier JG, editor. *Proceedings of the Fourth Drug and Therapeutics Bulletin symposium. From trial outcomes to clinical practice*. London: Which? Ltd, 1996: 5-10.
89. Aronson JK. Local anesthetics. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 19*. Amsterdam: Elsevier, 1996. Chapter 11.
90. Leuwer M , Z uzan O , A ronson J K. Neuromuscular b locking ag ents an d s keletal m uscle r elaxants. In: Aronson JK, V an B oxtel C J, e ditors. *Side E ffects o f D rugs, A nnu al 1 9*. A msterdam: E lsevier, 1996. Chapter 12.
91. Aronson JK. Cardiac glycosides and drugs used in dysrhythmias. In: Aronson JK, Van Boxtel CJ, editors. *Side Effects of Drugs, Annual 19*. Amsterdam: Elsevier, 1996. Chapter 17.
92. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Dukes MNG, editor. *Meyler's side effects of drugs*. 13th edition. Amsterdam: Elsevier, 1996: Chapter 17.
93. Aronson JK. General an esthetics an d t herapeutic g ases. In: A ronson J K, e ditor. *Side E ffects o f D rugs, Annual 20*. Amsterdam: Elsevier, 1997. Chapter 10.
94. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 20*. Amsterdam: Elsevier, 1997. Chapter 17.
95. Aronson JK. Antifungal d rugs. In: A ronson J K, e ditor. *Side E ffects o f D rugs, A nnu al 2 0*. A msterdam: Elsevier, 1997. Chapter 27.
96. Aronson JK. Prescribing in r enal in sufficiency: p rinciples a nd p ractice. In: J amison R L, W ilkinson R , editors. *Nephrology*. London: Chapman & Hall, 1997. Chapter 69.
97. Aronson JK. Routes of dr ug administration: 7 . S ubcutaneous a dministration. *Presc J* 1 998; 3 8: 5 0-5 (correspondence 195-6).
98. Aronson JK, Derry S. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 21*. Amsterdam: Elsevier, 1998. Chapter 17.
99. Aronson JK, Proudfoot AT. Principles of drug therapy and management of poisoning. In: C Haslett, ER Chilvers, JAA Hunter, NA Boon, editors. *Davidson's principles and practice of medicine*, 18th edition. Edinburgh: Churchill Livingstone, 1999. Chapter 19.
100. Aronson JK. Drugs and renal insufficiency. *Med Int* 1999; 27(7): 113-18.
101. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs, Annual 22*. Amsterdam: Elsevier, 1999. Chapter 17.
102. Aronson JK. Miscellaneous antibacterial drugs. In: Aronson JK, editor. *Side Effects of Drugs, Annual 22*. Amsterdam: Elsevier, 1999. Chapter 26.
103. Aronson JK. Drug absorption: achieving optimal clinical response. *Prescriber* 1999; 10(17): 45-54.

104. Aronson JK. Drug excretion: what the prescriber should know. *Prescriber* 1999; 10(20): 67-75.
105. Aronson JK. How drugs produce their pharmacological effects: 1. *Prescriber* 1999; 10(22): 19-26.
106. Aronson JK. How drugs produce their pharmacological effects: 2. *Prescriber* 1999; 10(23): 60-5.
107. Edwards IR, Aronson JK. Adverse drug reactions—definitions, classification, diagnosis, management, surveillance. *Lancet* 2000; 356(9237): 1255-60. [PMID: 11072960]
108. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 23. Amsterdam: Elsevier, 2000. Chapter 17.
109. Aronson JK. General principles of drug therapy. In: *Oxford textbook of psychiatry*. Oxford: Oxford University Press, 2000; Chapter 6.2.1: 1275-84.
110. Aronson JK. Neurological side-effects of drugs: an overview. *Prescriber* 2001; 12(5): 43-8.
111. Richards DB, Aronson JK. Pharmacological terms used in advertisements for antihypertensive drugs: what information do they give us? *Modern Hypertension Management* 2001; 3: 9-14.
112. Aronson JK. Antiepileptic drugs. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 25. Amsterdam: Elsevier, 2001. Chapter 7.
113. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 25. Amsterdam: Elsevier, 2002. Chapter 17.
114. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 25. Amsterdam: Elsevier, 2002. Chapter 17.
115. Aronson JK. Anti-infective drugs. In: S L Lock, J M Last, G Dunea, editors. *The Oxford Illustrated Companion to Medicine*. Third Edition. Oxford: OUP, 2002.
116. Aronson JK. Placebos. In: S L Lock, J M Last, G Dunea, editors. *The Oxford Illustrated Companion to Medicine*. Third Edition. Oxford: OUP, 2002.
117. Aronson JK. Drug therapy. In: Haslett C, Chilvers ER, Boon NA, Colledge NR, editors., Hunter JAA, international editor. *Davidson's Principles and Practice of Medicine*. 19th edition. Edinburgh: Elsevier Science Limited, 2002: 147-63.
118. Aronson JK. Plant poisons. In: G Cook, A Zumla, editors. *Manson's Tropical Diseases*, 2^{1st} edition. London: Harcourt International, 2002; Chapter 26.
119. Maxwell S, Walley T; BPS Clinical Section Committee. Teaching safe and effective prescribing in UK medical schools: a core curriculum for tomorrow's doctors. *Br J Clin Pharmacol* 2003; 55(6): 496-503. [PMID: 12814441]
120. Aronson JK. Drugs and renal insufficiency. *Med Int* 2003; 31(7): 103-9.
121. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 26. Amsterdam: Elsevier, 2003. Chapter 17.
122. Aronson JK. Heart failure. In: DJ Weatherall, D Warrell, J Firth, editors. *Oxford textbook of medicine*. Oxford: Oxford University Press, 2003; 2: 959-68.
123. Aronson JK. Drugs and renal insufficiency. *Surgery* 2003; 21: 104a-104f.
124. Aronson JK. Medication errors resulting from the confusion of drug names. *Expert Opin Drug Saf* 2004; 3(3): 167-72. [PMID: 15155145]
125. Aronson JK. Adverse drug reactions: an introduction. *Hosp Pharm Europe* 2004; 13 Mar/Apr.
126. Aronson JK. Neurological adverse drug reactions. *Hosp Pharm Europe* 2004; 15 Jul/Aug.
127. Aronson JK. Louis Lewin—Meyler's predecessor. In: Aronson JK (editor). *Side Effects of Drugs Annual* 27. Amsterdam: Elsevier, 2004: xxv-xxix.
128. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 27. Amsterdam: Elsevier, 2004. Chapter 17.
129. Aronson JK. Adjusting therapeutic dosage regimens to optimise the balance of benefit to harm. *Clin Med* 2005; 5(1): 16-19. [PMID: 15745191]
130. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 28. Amsterdam: Elsevier, 2005. Chapter 17.
131. Keeling DM, Aronson JK. Drugs affecting blood coagulation, fibrinolysis, and hemostasis. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 28. Amsterdam: Elsevier, 2005. Chapter 35.
132. Choulis NH, Aronson JK. Miscellaneous drugs and materials, medical devices, and techniques. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 28. Amsterdam: Elsevier, 2005. Chapter 49.
133. Aronson JK. Drug therapy. In: Boon NA, Colledge NR Walker BR, editors., Hunter JAA, international editor. *Davidson's Principles and Practice of Medicine*. 20th edition. Edinburgh: Churchill Livingstone, 2006: 17-35.
134. Aronson JK. Drugs and renal insufficiency. *The Foundation Years* 2006; 3 (1): 7 -13. doi.org/10.1016/j.mpfou.2006.11.003
135. Aronson JK. Industry-sponsored clinical research—an editor's view. In: Halkin H, Tal O, editors. *Patients, Physicians, and Pharma*. Haifa: The Israel National Institute for Health Policy Research, 2006: 15-28.
136. Aronson JK. Meyler's—cornerstone of the pharmacovigilance library. *Uppsala Reports* 2007; Jan: 21.
137. Aronson JK. Drugs and renal insufficiency. *Medicine* 2007; 35(7): 396-8. mpm.2007.04.013.

138. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. Side Effects of Drugs, Annual 29. Amsterdam: Elsevier, 2007. Chapter 17; doi 10.1016/S0378-6080(06)29017-2.
139. Choulis N H, Aronson J K. Miscellaneous drugs and materials, medical devices, and techniques. In: Aronson J K, editor. Side Effects of Drugs, Annual 29. Amsterdam: Elsevier, 2007. Chapter 49; doi 10.1016/S0378-6080(06)29049-4.
140. Aronson JK. General principles of drug therapy in psychiatry. In: Oxford textbook of psychiatry. Oxford: Oxford University Press, 2008; Chapter 6.2.1.
141. Glasziou P, Aronson JK. An introduction to monitoring therapeutic interventions in clinical practice. In: Glasziou P, Irwig L, Aronson J K, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell Publishing/BMJ Books, 2008: 3-14.
142. Aronson JK, Michie S. Developing monitoring tools: integrating the pathophysiology of disease and the mechanisms of action of therapeutic interventions. In: Glasziou P, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell Publishing/BMJ Books, 2008: 31-47.
143. Aronson JK. Biomarkers and surrogate endpoints in monitoring therapeutic interventions. In: Glasziou P, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell Publishing/BMJ Books, 2008: 48-62.
144. Coleman JJ, Ferner RE, Aronson JK. Monitoring for the adverse effects of drugs. In: Glasziou P, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford: Blackwell Publishing/BMJ Books, 2008: 194-210.
145. Goosens AE, Aronson JK. Dermatological drugs, topical agents, and cosmetics. In: Aronson JK, editor. Side Effects of Drugs, Annual 30. Amsterdam: Elsevier, 2008. Chapter 14; doi 10.1016/S0378-6080(08)00014-7.
146. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. Side Effects of Drugs, Annual 30. Amsterdam: Elsevier, 2008. Chapter 17; doi 10.1016/S0378-6080(08)00017-2.
147. Aronson JK. Medication errors. In: Aronson JK, editor. Side Effects of Drugs, Annual 30. Amsterdam: Elsevier, 2008. Chapter 50; doi 10.1016/S0378-6080(08)00063-9.
148. Aronson JK. Plant poisons. In: G Cook, A Zumla, editors. Manson's Tropical Diseases, 22nd edition. London: Harcourt International, 2009; Chapter 32: 601-26.
149. Aronson J K. Routes of drug administration: uses and adverse effects. Part 1: Intramuscular and subcutaneous injection. Adv Drug React Bull 2009; 253: 971-4.
150. Aronson JK. Routes of drug administration: uses and adverse effects. Part 2: Sublingual, buccal, rectal, and some other routes. Adv Drug React Bull 2009; 254: 975-8.
151. Aronson J K. Medication errors: what they are, how they happen, and how to avoid them. QJM 2009; 102(8): 513-21. [PMID: 19458202]
152. Aronson JK. Medication errors: definitions and classification. Br J Clin Pharmacol 2009; 67(6): 599-604. [PMID: 19594526]
153. Aronson JK. Anti-inflammatory and antipyretic analgesics and drugs used in gout. In: Aronson JK, editor. Side Effects of Drugs Annual 31. Chapter 9. Amsterdam: Elsevier Science, 2009: 181-215; doi 10.1016/S0378-6080(09)03101-8.
154. Aronson JK. Drugs that affect autonomic functions or the extrapyramidal system. In: Aronson JK, editor. Side Effects of Drugs Annual 31. Chapter 13. Amsterdam: Elsevier Science, 2009: 259-85; doi 10.1016/S0378-6080(08)03115-8.
155. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. Side Effects of Drugs Annual 31. Chapter 17. Amsterdam: Elsevier Science, 2009: 321-38; doi 10.1016/S0378-6080(09)03117-1.
156. Aronson JK. Diuretics. In: Aronson JK, editor. Side Effects of Drugs Annual 31. Chapter 21. Amsterdam: Elsevier Science, 2009: 371-81; doi 10.1016/S0378-6080(09)03121-3.
157. Aronson J K. Antifungal drugs. In: Aronson J K, editor. Side Effects of Drugs Annual 31. Chapter 27. Amsterdam: Elsevier Science, 2009: 457-67; doi 10.1016/S0378-6080(09)03127-4.
158. Aronson JK. Patent medicines and secret remedies. BMJ 2009; 339: b5415. [PMID: 20008435]
159. Aronson JK. Clinical pharmacology and therapeutics in the UK—a great instauration. Br J Clin Pharmacol 2010; 69(2): 111-7. [PMID: 20233173]
160. Aronson J K. Therapeutics and good prescribing. In: Colledge NR Walker BR, Ralston SH, editors. Davidson's Principles and Practice of Medicine. 21st edition. Edinburgh: Churchill Livingstone, 2010: Chapter 2.
161. Aronson JK. Positive inotropic drugs and drugs used in dysrhythmias. In: Aronson JK, editor. Side Effects of Drugs Annual 32. Chapter 17. Amsterdam: Elsevier Science, 2010: 333-62; doi 10.1016/S0378-6080(10)32017-4.

162. Aronson JK. Drugs that affect blood coagulation, fibrinolysis, and hemostasis. In: Aronson JK, editor. Side Effects of Drugs Annual 32. Chapter 35. Amsterdam: Elsevier Science, 2010: 617-63; doi 10.1016/S0378-6080(10)32035-6.
163. Aronson JK. Drugs that affect lipid metabolism. In: Aronson JK, editor. Side Effects of Drugs Annual 32. Chapter 44. Amsterdam: Elsevier Science, 2010: 803-26; doi 10.1016/S0378-6080(10)32044-7.
164. Aronson J K. Radiological contrast agents. In: Aronson J K, editor. Side Effects of Drugs Annual 32. Chapter 46. Amsterdam: Elsevier Science, 2010: 843-64; doi 10.1016/S0378-6080(10)32046-0.
165. Aronson JK. Medication errors. In: Aronson JK, editor. Side Effects of Drugs Annual 32. Chapter 50. Amsterdam: Elsevier Science, 2010: 903-22; doi 10.1016/S0378-6080(10)32050-2.
166. Aronson JK. Diuretics. In: Aronson JK, editor. Side Effects of Drugs Annual 33. Chapter 21. Amsterdam: Elsevier Science, 2011: 437-45; doi: 10.1016/B978-0-444-53741-6.00021-0.
167. Lartey M, Torpey K, Aronson JK. Antiviral drugs. In: Aronson JK, editor. Side Effects of Drugs Annual 33. Chapter 29. Amsterdam: Elsevier Science, 2011: 577-621; doi: 10.1016/B978-0-444-53741-6.00029-5.
168. Allwood MC, Aronson JK. Vitamins, intravenous solutions, and drugs and formulations used in nutrition. In: Aronson JK, editor. Side Effects of Drugs Annual 33. Chapter 34. Amsterdam: Elsevier Science, 2011: 691-706; doi: 10.1016/B978-0-444-53741-6.00034-9.
169. Aronson JK. Drugs that affect blood coagulation, fibrinolysis, and hemostasis. In: Aronson JK, editor. Side Effects of Drugs Annual 33. Chapter 35. Amsterdam: Elsevier Science, 2011: 707-39; doi: 10.1016/B978-0-444-53741-6.00035-0.
170. Aronson JK. Drugs that act on the immune system: immunosuppressive and immunostimulatory drugs. In: Aronson JK, editor. Side Effects of Drugs Annual 33. Chapter 38. Amsterdam: Elsevier Science, 2011: 815-39; doi: 10.1016/B978-0-444-53741-6.00038-6.
171. Aronson J K. Adverse drug reactions: history, terminology, classification, causality, frequency, preventability. In: Talbot J, Aronson JK, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell, 2011: 1-119.
172. Raine J, Wise L, Talbot J, Aronson JK. Proactive pharmacovigilance and risk management. In: Talbot J, Aronson JK, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell, 2011: 389-409.
173. Barker CIS, Talbot J, Aronson JK. Web sites relevant to pharmacovigilance—an analysis of contents. In: Talbot J, Aronson JK, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell, 2011: 685-97.
174. Aronson JK. Guidelines and a checklist for reporting suspected adverse drug reactions anecdotally in journals. In: Talbot J, Aronson J K, editors. Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition. Oxford: Wiley-Blackwell, 2011: 699-708.
175. Aronson J K. Evaluation of pharmacological evidence for forensic purposes. *Int J Risk Saf Med* 2012; 24(1): 3-12. doi 10.3233/JRS-2012-0547. [PMID:22436254]
176. Aronson JK. Plant poisons and traditional medicines. In: Farrar J, Hotez PJ, Junghanss T, Lalloo DG, White NJ, editors. Manson's Tropical Diseases, 2 3rd edition. London: Harcourt International, 2012; Chapter 69: in press.
177. Aronson JK. An agenda for UK clinical pharmacology: Research priorities in biomarkers and surrogate endpoints. *Br J Clin Pharmacol* 2012; 73(6): 900-7. doi: 10.1111/j.1365-2125.2012.04234.x. [PMID:22360291]
178. Buclin T, Gotta V, Fuchs A, Widmer N, Aronson J K. An agenda for UK clinical pharmacology: Monitoring drug therapy. *Br J Clin Pharmacol* 2012; 73(6): 917-23. doi: 10.1111/j.1365-2125.2012.04237.x. [PMID:22360377]
179. Green A R, Aronson J K. An agenda for UK clinical pharmacology: from basic to clinical neuropharmacology—targetophilia or pharmacodynamics? *Br J Clin Pharmacol* 2012; 73(6): 959-67. doi: 10.1111/j.1365-2125.2012.04246.x. [PMID:22360689]
180. Aronson JK. Balanced prescribing—principles and challenges. *Br J Clin Pharmacol* 2012; 74(4): 566-72.
181. Swales C, Aronson JK. Medication and health in the workplace. In: 2012: in press.
182. Aronson JK. Case reports as evidence in pharmacovigilance. In: Mann's Pharmacovigilance. 3rd edition. Oxford: Wiley-Blackwell, in press.

F Presentations to national and international learned societies; letters to journals; other occasional pieces

1. Aronson JK, Arthur F, Grahame-Smith DG, Hallis KF. Monitoring digoxin therapy: the use of erythrocytic ⁸⁶Rb uptake. *Br J Clin Pharmacol* 1975; 2(2): 187-8P. [PMCID: PMC1402511]
2. Grahame-Smith DG, Aronson JK, Boullin DJ, Orr M. Proceedings: Cellular biochemical pharmacology in monitoring drug therapy. *Arzneimittelforschung* 1976; 26(6): 1256-7. [PMID: 989454]

3. Aronson J K, Ford A R. The use of quantitative colour vision testing in diagnosing digitalis toxicity. Presented to the 7th International Congress of Pharmacology, Paris, 1978.
4. Grahame-Smith DG, Aronson JK, Ford AR. The effect of digoxin therapy on red blood cell function and its relationship to the therapeutic response. In: Proceedings of the 7th International Congress of Pharmacology, Paris, 1978.
5. Royer RJ, Zannad F, Robert J, Royer MJ, Grahame-Smith DG, Aronson JK. Monitoring digoxin therapy: comparison between tissue response and clinical effects. Presented to the 7th International Congress of Pharmacology, Paris 1978.
6. Aronson JK, Ford AR, Grahame-Smith DG. The pharmacological effects of digoxin which occur during the short-term treatment do not persist in the long-term. *Q J Med* 1979; NS48: 644.
7. Aronson JK. The effects of digoxin on red cell digitalis receptor function in man. Presented to the First World Conference on Clinical Pharmacology and Therapeutics, London, 1980.
8. Green AR, Aronson JK. The metabolism of oral L-tryptophan. Presented to the First World Conference on Clinical Pharmacology and Therapeutics, London, 1980.
9. Willoughby CP, Aronson JK, Agback H, Bodin NO, Anderson E, Truelove SC. Disposition in normal volunteers of sodium diazosalicylate, a potential therapeutic agent in inflammatory bowel disease. *Gut* 1981; 22: A431.
10. Aronson J K, Carver J G. Interaction of digoxin with quinine. *Lancet* 1981; 1(8235): 1418. [PMID: 6113370]
11. Pugh SE, White NJ, Aronson JK, Grahame-Smith DG, Carver JG. Erythrocytic digoxin receptor numbers and activity: relation to clinical changes following digoxin withdrawal after long-term treatment for heart failure in sinus rhythm. *Br J Clin Pharmacol* 1982; 13(2): 271-2P. [PMCID: PMC1401983]
12. Aronson JK, Grahame-Smith DG, Hallis KF, White NJ. The effect of digoxin on the in vivo disposition of an oral load of rubidium chloride. *Br J Clin Pharmacol* 1982; 13(4): 606-7P. [PMCID: PMC1402046]
13. Boon NA, Hallis KF, Aronson J K, Pugh S, Conway J, Grahame-Smith D G. The disposition of oral rubidium chloride in essential hypertension. *Clin Sci (Lond)* 1982; 63: 68P.
14. Boon N, Aronson J K. Sodium efflux and essential hypertension. *Lancet* 1982; 2(8308): 1160. [PMID: 6128474]
15. Aronson J K, Moore M P, Redman C W, Harper C. Sodium-lithium countertransport in erythrocytes of pregnant women. *N Engl J Med* 1982; 307(26): 1645-6. [PMID: 7144857]
16. Boon NA, Oh VMS, Taylor EA, Johansen T, Aronson JK, Grahame-Smith DG. [³H]-ouabain binding and ⁸⁶rubidium uptake in polymorphonuclear and mononuclear leucocytes. *Br J Clin Pharmacol* 1983; 15(5): 617P. [PMCID: PMC1427722]
17. Oh VMS, Taylor EA, Boon NA, Aronson JK, Grahame-Smith DG. Stimulation of [³H]-ouabain binding to intact human lymphocytes by normal human and fetal calf serum. *Br J Clin Pharmacol* 1983; 15(5): 618P. [PMCID: PMC1427722]
18. Aronson J K, Carver J G. Diagnosing digoxin toxicity by combined measurement of plasma digoxin concentrations and erythrocytic ⁸⁶rubidium uptake. *Br J Clin Pharmacol* 1983; 15(5): 618-9P. [PMCID: PMC1427722]
19. Boon NA, Rose J A, Hallis K F, Jones J V, Manley B S, Aronson J K. Evidence that cation transport is reduced in vivo in one-kidney one clip hypertension. Presented to the First European Meeting on Hypertension, Milan, 1983.
20. Aronson JK, Boon NA, Hallis KF, Pugh SE, Grahame-Smith DG. In vivo disposition on oral rubidium: effect of short-term and long-term digoxin. Presented to the Second World Conference on Clinical Pharmacology and Therapeutics, Washington DC, 1983.
21. Boon NA, Raine AE, Hallis K F, Perkins C M, Grahame-Smith D G, Aronson J K. In vivo evidence of reduced cation transport in chronic renal failure. *Clin Sci (Lond)* 1983; 65: 60P.
22. Boon NA, Pugh SE, Hallis KF, Aronson JK, Grahame-Smith DG. Evidence that cation transport in vivo is inhibited by short-term but not long-term digoxin therapy. *Br Heart J* 1984; 51: 690.
23. Rapeport WG, Aronson JK, Grahame-Smith DG, Harper C. The effects of lithium, ethacrynic acid, and low potassium on specific lymphocyte [³H]-ouabain binding. *Br J Clin Pharmacol* 1985; 20(3): 259P. [PMCID: PMC1400698]
24. Rapeport WG, Aronson JK, Grahame-Smith DG, Harper C. Increased specific [³H]-ouabain binding to lymphocytes after incubation with acetylcholinesterase inhibitor for 3 days. *Br J Clin Pharmacol* 1985; 20(3): 277-8P. [PMCID: PMC1400698]
25. Hardman M, Viswalingam A, Pridmore J D, Aronson J K, Grahame-Smith D G. Partial purification and characterization of an endogenous inhibitor of Na,K-ATPase. Presented to the Third World Conference on Clinical Pharmacology and Therapeutics, Stockholm, 1986.
26. Wood AJ, Viswalingham A, Aronson JK, Grahame-Smith DG. The effect of lithium on cation transport in vivo and in vitro in healthy volunteers. *Br J Clin Pharmacol* 1987; 23(5): 609-10P. [PMCID: PMC1386199]

27. Kennedy DG, Bloomfield JG, Aronson JK, Grahame-Smith DG. The effect of a low external potassium concentration on the Na/K-ATPase of human lymphoblasts. *Br J Clin Pharmacol* 1987; 23 (5): 639P. [PMCID: PMC1386199]
28. Wood AJ, Aronson JK, Cowen PJ, Grahame-Smith DG. In vivo measurement of cation transport in patients suffering from acute manic illness. Presented to a conference on New Directions in Affective Disorder, Jerusalem, 1987.
29. Wood AJ, Brearley CJ, Aronson JK, Grahame-Smith DG. The effects of salbutamol on in vivo cation transport. *Br J Clin Pharmacol* 1988; 25(5): 624-5P. [PMCID: PMC1386439]
30. Brearley CJ, Wood AJ, Aronson JK, Grahame-Smith DG. The in vivo disposition of lithium in patients with untreated essential hypertension. *Clin Sci (Lond)* 1988; 75: 55P.
31. Syme PD, Allis JL, Dixon RM, Aronson JK, Grahame-Smith DG, Radda GK. Quantification of rubidium concentrations in rat muscle in vivo using high resolution nuclear magnetic resonance spectroscopy. Presented to the Seventh Annual Meeting of the Society of Magnetic Resonance in Medicine, San Francisco 1988.
32. Jenkins RJ, Aronson JK. The effects of lithium on Na/K pump numbers and activity in isolated human lymphocytes in vitro. *Br J Clin Pharmacol* 1989; 27(5): 654-5P. [PMCID: PMC1379936]
33. Moraes, MEA de, Aronson JK, Grahame-Smith DG. The pharmacokinetics of intravenous stable strontium in healthy volunteers. *Br J Clin Pharmacol* 1989; 27(5): 673-4P. [PMCID: PMC1379936]
34. Moraes, MEA de, Aronson JK, Grahame-Smith DG. The effect of the calcium antagonist nifedipine on the disposition of strontium after the intravenous infusion of stable strontium gluconate. *Q J Med* 1989; NS73: 971-2.
35. Brearley CJ, Wood AJ, Aronson JK, Grahame-Smith DG. In vivo measurement of the rate and stoichiometry of sodium/sodium countertransport in human erythrocytes and the effects of essential hypertension. *Q J Med* 1989; NS73: 972-3.
36. Jenkins RJ, Ng LL, Aronson JK. Increased intracellular pH and Na/H exchange in lymphocytes exposed to lithium for 72 h. *Eur J Clin Pharmacol* 1989; 36: A91.
37. Syme PD, Dixon RM, Aronson JK, Grahame-Smith DG, Radda GK. Evidence for increased in vivo Na⁺/K⁺-ATPase activity in skeletal muscle of spontaneously hypertensive rats. *Clin Sci (Lond)* 1990; 78: 8P.
38. Syme PD, Arnold L, Green Y, Aronson JK, Grahame-Smith DG, Radda GK. Evidence for increased in vivo Na⁺/H⁺ antiporter activity in skeletal muscle of spontaneously hypertensive rats. *Clin Sci (Lond)* 1990; 78: 8P.
39. Syme PD, Arnold L, Green Y, Aronson JK, Radda GK. Evidence for increased Na⁺/H⁺ antiporter activity in skeletal muscle of spontaneously hypertensive rats, measured by NMR spectroscopy. Presented to the 13th scientific meeting of the International Society of Hypertension, 1990.
40. Syme PD, Arnold L, Green Y, Aronson JK, Radda GK. Altered contractile response in skeletal muscle of spontaneously hypertensive rats in association with increased in vivo Na⁺/H⁺ antiporter activity. Presented to the 13th scientific meeting of the International Society of Hypertension, 1990.
41. Ameen M, Bloomfield J, Aronson JK. The effects of a low extracellular concentration of potassium for 72 h on Na/K pump numbers and activity in human lymphoblasts and their reversal within 24 h. *Br J Pharmacol (Proc Suppl)* 1990; 100: 470P.
42. Syme P, Arnold L, Aronson JK, Radda GK. Increased Na⁺-H⁺ antiport activity in vivo in skeletal muscle of spontaneously hypertensive rats can be reversed by nifedipine. *J Hypertens* 1990; 8: 1064-5.
43. Aronson JK, Jenkins RJ, Ng LL. Regulation of the activity of the Na/K-ATPase —the effect of lithium and the mechanism of its action. *Trace Elements Med* 1990; 7: 94-5.
44. Wood AJ, Smith CE, Clarke EE, Cowen PJ, Aronson JK, Grahame-Smith DG. Altered adaptive responses of the lymphocyte Na⁺,K⁺-ATPase in bipolar affective illness. *Biol Psychiatry* 1991; 29: 318S.
45. Ameen M, Peek AR, Aronson JK, Lamb JF. The cellular distribution of Na/K pumps in human lymphoblasts after exposure to a low extracellular concentration of potassium. *Br J Pharmacol (Proc Suppl)* 1992; 105: 207P.
46. Ameen M, Aronson JK, Lamb JF. Long term effects of growth in low K medium on sodium pump activity in human cultured cells. *J Physiol (Lond)* 1993; 459: 43P.
47. Aronson JK, Reynolds DJM. Monitoring lithium treatment: Authors' reply. *BMJ* 1993; 306(6872): 270. [PMCID: PMC1676716]
48. Aronson JK, Reynolds DJM. Monitoring theophylline treatment: Authors' reply. *BMJ* 1993; 306(6875): 457. [PMCID: PMC1676551]
49. Aronson JK, Reynolds DJM. Monitoring treatment with aminoglycoside antibiotics: Authors' reply. *BMJ* 1993; 306(6874): 392-3. [PMCID: PMC1676433]
50. Vanags DM, Bloomfield J, Aronson JK, Grahame-Smith DG. Pharmacological characterization of potassium channels on human platelets. Presented to the Sixth International Symposium on Pharmacological Control of Calcium and Potassium Homeostasis, Florence 1994.

51. Smith CC, Bennett PM, Pearce HM, Reynolds DJ, Aronson JK, Grahame-Smith DG. NSAIDs and gut toxicity. *Lancet* 1994; 344(8914): 56-7. [PMID: 7912318]
52. Murton RA, Aronson JK. Upregulation of sodium/potassium pumps by the loop diuretic ethacrynic acid—possible role of phosphoinositide turnover. *Br J Pharmacol Proc Suppl* 1995; 114: 240P.
53. Murton RA, Aronson JK. Upregulation of Na/K pumps by loop diuretics—non-involvement of Na/K/2Cl co-transport. *Br J Pharmacol Proc Suppl* 1995; 116: 154P.
54. De Silva HA, Carver JG, Aronson JK. Stimulation of potassium (⁸⁶Rubidium) efflux from human platelets by external potassium and its inhibition by bumetanide—evidence for Na/K/Cl co-transport. *Br J Pharmacol Proc Suppl* 1996; 117: 115P.
55. De Silva HA, Carver JG, Aronson JK. Calcium-activated and ATP-dependent potassium channels in human platelets. *Br J Pharmacol Proc Suppl* 1996; 118: 102P.
56. De Silva HA, Aronson JK. Evidence for calcium-dependent (K_{Ca}) and voltage-dependent (K_v) potassium channels in human platelets. *Pharmacologist* 1997; 39: 57.
57. Aronson JK, De Silva HA. Evidence for potassium/chloride co-transporters in human platelets. *Pharmacologist* 1997; 39: 59.
58. Murton RA, Aronson JK. Upregulation of Na/K pumps by ethacrynic acid: role of altered phosphoinositide (PI) hydrolysis. *Pharmacologist* 1997; 39: 63.
59. De Silva HA, Aronson JK. Interaction between the Na⁺/K⁺/2Cl⁻ co-transporters in human platelets. *Br J Pharmacol Proc Suppl* 1997; 122: 92P.
60. Aronson JK. Digoxin revisited. *QJM* 1998; 91(10): 713. [PMID: 10024931]
61. Mendes Ribeiro AC, Brunini TMC, Aronson JK, Ellory JC, Mann GE. L-arginine transport in human platelets is mediated by the high affinity amino acid transport system y⁺L. *J Physiol (Lond)* 1999; 517: 26P.
62. John NG, Aronson JK. Effects of homocysteine on potassium channels in human platelets. *Br J Pharmacol Proc Suppl* 1999; 128: 253P.
63. Brunini TMC, Ashman N, Yaqoob M, Aronson JK, Ellory JC, Mann GE, Mendes Ribeiro AC. Homocysteine inhibition of system y⁺L in human platelets: implications for atherosclerosis in uraemia. *J Physiol* 2000; 000: 000.
64. Thomas J, Phipps S, Aronson JK. Effects of homocysteine, cysteine, and methionine on charybdotoxin-sensitive potassium channels in human platelets. *Proc West Pharmacol Soc* 2001.
65. Richards DBJ, Aronson JK. Stimulation of cation flux in human platelets by physiological concentrations of angiotensin: possible relevance to monitoring of the actions of ACE inhibitors. *Proc West Pharmacol Soc* 2001.
66. Ferner RE, Aronson JK. Adverse events in British hospitals. Retrospective case record analysis has been superseded. *BMJ* 2001; 322(7299): 1427. [PMID: 11417562]
67. de Silva HA, Fonseka MD, Pathmeswaran A, Ratnatilake GA, Alahakoon DGS, Ranasinha CD, Gunatilake SB, Lalloo DG, Aronson JK, de Silva HJ. Treatment of yellow oleander poisoning with multiple-dose activated charcoal: a randomized placebo-controlled trial. *Br J Clin Pharmacol* 2003; 55(4): 422-3. [PMCID: PMC1884242]
68. Aronson JK, Derry S, Loke YK. Assessing perceptions of benefit and harm of common drug therapies using therapeutic scenarios. *Br J Clin Pharmacol* 2003; 55(4): 438. [PMCID: PMC1884242]
69. Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal adverse drug reactions as pure gold and high grade ore. *Drug Saf* 2006; 29(10): 953.
70. Hauben M, Aronson JK. Paradoxical reactions: under-recognized adverse effects of drugs. *Drug Saf* 2006; 29(10): 970.
71. Aronson JK, Barnett DB, Ferner RE, Ferro A, Henderson G, Maxwell SR, Rawlins MD, Webb DJ. Poor prescribing is continual. *BMJ* 2006; 333(7571): 756. [PMID: 17023482]
72. Aronson JK. Glomerular filtration rate: eGFR in changing drug regimens. *BMJ* 2007; 334(7607): 1287. [PMID: 17585126]
73. Aronson JK, Hauben M. Between-the eyes adverse drug reactions. *Cochrane Colloquium*, Dublin 2006.
74. de Silva HA, Pathmeswaran A, Lalloo DG, de Silva HJ, Aronson JK. Multiple-dose activated charcoal in yellow oleander poisoning. *Lancet* 2008; 371(9631): 2171. [PMID: 18586169]
75. Aronson JK. Observational evidence for determining drug safety: too high a pedestal. *BMJ* 2008; 336(7647): 735. [PMID: 18390501]
76. Aronson JK. Publishing histories of adverse reactions to medications and ecodotally: the PHARMA guidelines for reporting suspected adverse drug reactions. *Drug Saf* 2008; 31(4): 355-6. [PMID: 18366246]
77. Aronson JK. Message from the President. *pA₂* 2008; 6(1): 3-4.
78. Aronson JK. The pharmacological network. *Pharmacol Matters* 2008; 1(2): 6-7.

79. Aronson JK, Barnett DB, Breckenridge AM, Ferner RE, Jackson P, Maxwell SR, McInnes GT, Rawlins MD, Ritter JM, Routledge P, Walley TJ, Webb DJ, Williams D, Woods KL. The UK's NHS and pharma: need for more clinical pharmacologists. *Lancet* 2009; 373(9671): 1251-2. [PMID: 19362673]
80. Aronson JK. Increasing access to medicines. Time for category of pharmacist consultation and supply. *BMJ* 2009; 338: b1899. doi: 10.1136/bmj.b1899. [PMID: 19435767]
81. Aronson JK. Balanced prescribing and the information that we need to achieve it. *Basic Clin Pharmacol Toxicol* 2009; 105 (Suppl 1): 3-4.
82. Hughes DA, Aronson JK. A systematic review and empirical analysis of the relation between dose and duration of drug action. *Basic Clin Pharmacol Toxicol* 2009; 105 (Suppl 1): 32.
83. De Silva HA, Ranasinha CD, Pathmeswaran A, Lalloo D, Armitage J, Aronson JK, De Silva HJ. Prevention of acute adverse reactions to antivenom in snakebite: interim report of blinded data from a randomised, controlled trial. *BPS Summer Meeting* 2009; 081P. pA2 online. <http://www.pa2online.org/abstract/abstract.jsp?abid=29403&author=De%20Silva&cat=-1&period=42>.
84. Aronson JK. Pharmacologists in the Oxford Dictionary of National Biography. *Pharmacol Matters* 2009; 2(1): 24-5.
85. Aronson JK. A great instauration. *Pharmacol Matters* 2009; 2(3): 4-7.
86. Aronson JK. CPT or huliatics? *Pharmacol Matters* 2009; 2(3): 22-3.
87. Aronson JK. A model for academic clinicians. *Pharmacol Matters* 2009; 2(3): 24-5.
88. Weetman T, Aronson J, Maxwell S. Reducing prescription errors. *Lancet* 2010; 375(9713): 461-2. [PMID: 20152541]
89. Aronson JK, Maxwell S. Preparedness of Foundation Year doctors to prescribe. *Postgrad Med J* 4 Dec 2008. http://pmj.bmj.com/content/85/1009/582/reply#postgradmedj_el_5474.
90. Aronson JK. A manifesto for clinical pharmacology. *Pharmacol Matters* 2010; 3(1): 35-8.
91. Aronson JK. Found in translation: human pharmacology comes of age. *Basic Clin Pharmacol Toxicol* 2010; 107 (Suppl 1): 693.
92. Li N, Aronson J. The test dose—how to be a more valuable and reliable predictor? *Basic Clin Pharmacol Toxicol* 2010; 107 (Suppl 1): 411.
93. Aronson JK, Ferner RE. Length of treatment. Three questions for prescribers. *BMJ* 2010; 341: c5013. doi: 10.1136/bmj.c5013. [PMID: 20843922]
94. Aronson JK. 6/60 Vision: Celebrating the BNF and BNFC. <http://blogs.bmj.com/bmj/2010/11/24/jeffrey-aronson-660-vision-celebrating-the-bnf-and-bnfc/>.
95. Aronson JK. Integrating pharmacology and clinical pharmacology. *Br J Clin Pharmacol* 2011; 71(5): 787-90.
96. Barker CIS, Aronson JK. National pharmacovigilance websites: clarity and communication. *Br J Clin Pharmacol* 2011; 71(6): 986.
97. Barker CIS, Aronson JK. Sialadenitis due to iodinated contrast media ('iodide mumps')—evidence for two separate mechanisms. *Basic Clin Pharmacol Toxicol* 2011; 109 Suppl 1: 87.
98. Ramachandran M, Aronson JK. Authors' response to Hasan. *J R Soc Med* 2011; 104(9): 350. [PMID: 21881083]
99. Iessa N, Star K, Wilton L, Curran S, Edwards IR, Aronson JK, Murray M, Besag FM, Wong IC. Montelukast and suicide: causality assessment using spontaneous reports and Bradford Hill guidelines. *Drug Saf* 2011; 34(10): 949-50.
100. Aronson JK. David Grahame-Smith. *BMJ* 2011; 343: d6378. doi: 10.1136/bmj.d6378.
101. Aronson JK. David Grahame Grahame-Smith: Clinical pharmacologist 1933–2011. *Br J Clin Pharmacol* 2011 Dec 6. doi: 10.1111/j.1365-2125.2011.04160.x. [PMID: 22142441]
102. Aronson JK. System rather than target driven approach needed to discover beneficial drug effects. *BMJ* 2012; 344: e543. doi: 10.1136/bmj.e543. [PMID: 22275412]
103. Aronson JK. Surrogate endpoints: studying their benefits, taxonomy, and semantics. *BMJ* 2012; 344: e750. doi: 10.1136/bmj.e750. [PMID: 22293384]
104. Floor-Schreuder A, Geerts AF, Aronson JK, Bouvy ML, Ferner RE, Smet PAGMD. Towards improved drug-drug interaction management guidelines. *European Society of Clinical Pharmacy, 41st Symposium, Barcelona, Spain. 29-31 October 2012: ESCP12-1432*.
105. Iessa N, Star K, Murray ML, Wilton L, Curran S, Edwards IR, Aronson JK, Besag F, Wong ICK. An evaluation of the evidence of an association between montelukast and suicide: a publicity exacerbated signal? *Drug Saf* 2012; 35(10): 901.

G Medical language

Articles on medical words in the BMJ, under the general heading "When I Use a Word ...".

1. Curious, yellow. 1996; 312(7022): 28.
2. Wine and roses. 1996; 312(7024): 178.

3. Here's mud in your eye. 1996; 312(7027): 373.
4. Who was Fuller? 1996; 313(7056): 534.
5. Old chestnuts. 1996; 313(7058): 670.
6. Regime, regimen, regiment. 1996; 313(7058): 673.
7. $H_2 \neq H_2$. 1996; 313(7061): 873.
8. Ae, ae, ae! 1996; 313(7066): 1201.
9. Hiccup. 1996; 313(7068): 1326.
10. Got an ology? 1997; 314(7073): 28.
11. Shalom Salmonella. 1997; 314(7073): 49.
12. A time to be born. 1997; 314(7085): 973.
13. Sloe gin. 1997; 314(7087): 1106.
14. Fortysomething. 1997; 314(7095): 1674.
15. Difficult pronunciation. 1997; 315(7100): 107.
16. Quacks. 1997; 315(7101): 165.
17. Oe no! 1997; 315(7102): 225.
18. Hippopotamonstrorsesquipedalian. 1997; 315(7103): 292.
19. Buyers and sellers. 1997; 315(7106): 483.
20. Sausages. 1997; 315(7108): 599.
21. Wool gathering. 1997; 315(7112): 840.
22. Fingerprints. 1997; 315(7113): 930.
23. Crosses and stars. 1997; 315(7123): 1658.
24. What's my name? 1998; 316(7125): 124.
25. Spurious words. 1998; 316(7130): 534.
26. Medical Greek. 1998; 316(7134): 845. [PMCID: PMC1112774]
27. Fillers. 1998; 316(7149): 1990. [PMCID: PMC1113435]
28. Protean elephants. 1998; 317(7150): 89. [PMID: 9651302]
29. The venereal game. 1998; 317(7157): 535. [PMCID: PMC1113761]
30. Grapes. 1998; 317(7159): 688. [PMCID: PMC1113857]
31. Homogenous/homogeneous. 1999; 318(7180): 376. [PMCID: PMC1114842]
32. Please, please me. 1999; 318(7185): 716. [PMCID: PMC1115150]
33. Hepatojugular reflux. 1999; 318(7192): 1172. [PMCID: PMC1115583]
34. X marks the spot. 1999; 318(7197): 1543. [PMCID: PMC1115907]
35. Oranges and grapefruit. 1999; 318(7200): 1758. [PMCID: PMC1116091]
36. Allergy and immunity. 1999; 319(7205): 308. [PMCID: PMC1126941]
37. Now concentrate. 1999; 319(7208): 494. [PMCID: PMC1116388]
38. That's show business. 1999; 319(7215): 972. [PMCID: PMC1116803]
39. Fin de siècle countdown. 1999; 319(7225): 1595. [PMCID: PMC1127082]
40. Modern English Abuse. 2000; 320(7231): 357. [PMCID: PMC1127144]
41. Overate? 2000; 320(7235): 625. [PMCID: PMC1117655]
42. NICE? 2000; 320(7237): 749.
43. Cheque your spelling. 2000; 320(7240): 990. [PMID: 10753156]
44. Monthly injections. 2000; 320(7241): 1071. [PMID: 10764374]
45. Say cee. 2001; 321(7261): 611. [PMID: 10977841]
46. Chickenpox. 2001; 321(7262): 682. [PMID: 10987775]
47. An/anatomy. 2001; 321(7266): 953. [PMID: 11030692]
48. A medical alphabet. 2001; 321(7276): 1598. [PMID: 11124194]
49. The last word. 2001; 322(7289): 782. [PMCID: PMC1119958]
50. Oh? Why? 2001; 322(7292): 967. [PMCID: PMC1120136]
51. Re: re-. 2001; 322(7295): 1166. [PMCID: PMC1120287]
52. -ize right. 2001; 323(7322): 1173. [PMCID: PMC1121647]
53. A Christmas quiz. 2001; 323(7327): 1497. [PMCID: PMC1121919]
54. Terrorist. 2002; 324(7333): 355. [PMCID: PMC1122275]
55. Medicalization. 2002; 324(7342): 904. [PMCID: PMC1122839]
56. Round the back. 2002; 324(7343): 957. [PMCID: PMC1122903]
57. Meta-. 2002; 324(7344): 1022. [PMCID: PMC1122956]
58. Masses and masses. 2002; 324(7352): 1521. [PMCID: PMC1123453]
59. Ough ough. 2002; 325(7356): 160. [PMCID: PMC1123679]
60. When I use a mocking bird. 2002; 325(7358): 245. [PMCID: PMC1123773]
61. Patient centred verbs. 2002; 325(7360): 387. [PMCID: PMC1123893]
62. Man hater. 2003; 326(7382): 216. [PMCID: PMC1125069]
63. Wholly, holy, holey. 2003; 326(7385): 392. [PMCID: PMC1125246]
64. Dropsy. 2003; 326(7387): 491. [PMCID: PMC1125373]
65. The eyes have it. 2003; 326(7390): 639. [PMCID: PMC1125537]
66. Anecdoteage. 2003; 327(7426): 1276. [PMCID: PMC286252]
67. HARMful reactions. 2004; 328(7449): 1173. [PMCID: PMC411096]
68. Balancing benefits and harms in health care. 2004; 329(7456): 30. [PMCID: PMC443449]
69. Medical emoticons. 2005; 330(7482): 87. [PMCID: PMC543876]
70. Faux amis. 2005; 330(7498): 1006. [PMCID: PMC557151]
71. Rabid responses. 2005; 331(7513): 383. [PMCID: PMC1184250]
72. Bottled lightning. 2005; 331(7520): 824. [PMCID: PMC1246084]

73. Incestuous sheets. 2005; 331(7529): 1378. [PMCID: PMC1309647]
74. The very last word. 2006; 332(7540): 535. [PMCID: PMC1388135]
75. Nauseated/nauseous. 2006; 332(7552): 1271. [PMCID: PMC1471970]
76. Rare diseases, orphan drugs, and orphan diseases. 2006; 333(7559): 127. [PMCID: PMC1502161]
77. Sometimes, never. 2006; 333(7565): 445. [PMCID: PMC1553544]
78. Consultation. 2006; 333(7571): 737. [PMCID: PMC1592389]
79. The matter with 'issue'. 2006; 333(7577): 1059. [PMCID: PMC1647343]
80. Colourful metals. 2007; 334(7586): 205. [PMCID: PMC1781989]
81. Geographic metals. 2007; 334(7587): 258. [PMCID: PMC1790748]
82. No effect. 2007; 334(7593): 578. [PMCID: PMC1828314]
83. Words that count. 2007; 334(7603): 1104. [PMCID: PMC1877929]
84. Tom Swifties. 2008; 337: a836.
85. Spitting images. 2010; 340: b5064.
86. Formularies and pharmacopoeias. 2011; 342: d34.
87. Found in translation. 2011; 342: 2762.
88. Twice blessed. 2011; 343: d6281.
89. Lickerish liquorice. 2012; 344: e1453.
90. Hard data, soft data. 2012; 344: e1692.

Articles in the Quarterly Journal of Medicine, under the general heading "When I Use a Word ...".

1. Ordinary words with extraordinary meanings. 2008; 101(12): 993-4.
2. Words misheard—medical mondegreens. 2009; 102(4): 301-2. [Epub 2009 Jan 21] [PMID: 19158157]
3. Fulsomely banning 'compendious'. 2009; 102(7): 509-10. [Epub 2009 Apr 8] [PMID: 19359252]
4. Is it inflammation It is! 2009; 102(12): 895-6. [Epub 2009 Apr 15] [PMID: 19369482]
5. Changing your practice. 2010; 103(1): 63-5. [Epub 2009 May 21] [PMID: 19465373]
6. Declarative titles. 2010; 103(3): 207-9. [Epub 2009 Jun 29] [PMID: 19564241]
7. Materia medica, clinical pharmacology, and therapeutics. 2010; 103(5): 361-3. [Epub 2009 Jul 22] [PMID: 19625349]
8. Sex, gender, and segeny. QJM 2011; 104(7): 633-5. [Epub 2011 Jan 11] [PMID: 21224328]
9. Misunderspellings. QJM 2011; 104(12): 1109-10. [Epub 2011 Aug 24] [PMID: 21865310]
10. Innovations—"The Births of Time". QJM 2012; 105(10): 1037-9. [Epub 2012 Jun 11] [PMID: 22690008]

Other word articles

1. Aronson J K. "Where name and image meet"—the argument for "adrenaline" BMJ 2000; 320: 506–9. [PMID: 10678871]
2. Aronson JK. Francis Galton and the invention of terms for quantiles. J Clin Epidemiol 2001; 54: 1191–4. [PMID: 11750187]
3. Aronson JK. Disco dancing. Cytopathology 2002; 13(5): 326-7. [PMID: 12421449]
4. Aronson JK. When I Use a Word ... Mabs. Br J Gen Pract 2004; 54(504): 559. [PMCID: PMC1324822]
5. Aronson JK. When I Use a Word ... Goitre/goiter. Rev Argent Endocrinol Metab 2012; in press.

H Medical humanities

1. Aronson JK. Medicine in Staffordshire. Br Med J 1977; 1(6067): 1031-2. [PMID: 322810]
2. Aronson JK. An Account of the Foxglove and its Medical Uses 1785-1985. Oxford: Oxford University Press, 1985 [incorporating a facsimile of William Withering's monograph An account of the foxglove ... (1785) in a specially annotated edition]. ISBN 0-19-261501-7. [Spanish translation by D Mario Petit Guinovart & Juan Hernández Herrero, 1988.]
3. Aronson JK. The discovery of the foxglove as a therapeutic agent. Chem Brit 1987; 23: 33-6.
4. Aronson JK. Coloured discovery? New Scientist 1990; 30 June: 80-1.
5. Aronson JK. Classics in clinical pharmacology and therapeutics. Penicillin. Eur J Clin Pharmacol 1992; 42(1): 1-9. [PMID: 1541305] [Also at www.jameslindlibrary.org]
6. Aronson JK. Drugs—their history. Streptomycin. Med Int 1993; 21(6): vi-vii.
7. Aronson JK. Drugs—their history. Lithium. Med Int 1993; 21(7): vi.
8. Aronson JK. Drugs—their history. Methotrexate. Med Int 1993; 21(9): v-vi.
9. Aronson JK. A brief defence of curiosity. Oxf Mag 1994; 111: 3-4.
10. Aronson JK. Green College and the history of medicine. Green Coll Rec 1999: 11-13.
11. Aronson JK. Autopathography—the patient's tale. BMJ 2000; 321(7276): 1599-1602. [PMID: 11124195]
12. Aronson JK. John Coakley Lettsom and the introduction of digitalis into clinical practice at the end of the eighteenth century. Trans Med Soc Lond 2002-3; 119: 77-85. [PMID: 17184033]

13. Aronson JK. Signs of love, not a love potion. [Commentary on Weitz G. Love and death in Wagner's *Tristan und Isolde*. —an epic anticholinergic crisis.] *BMJ* 2003; 327(7429): 1471-2. [PMID: 14684653]
14. Aronson JK. Louis Lewin—Meyler's predecessor. In: Aronson JK, editor. *Side Effects of Drugs*, Annual 27. Amsterdam: Elsevier, 2005: xxv-xxix.
15. Aronson JK. William Osler. The teacher with open arms. *Oxford Today* 2005; 17(3): 17.
16. Ramachandran M, Aronson JK. The diagnosis of art: arthrogryposis and Ribera's *The Clubfoot*. *J R Soc Med* 2006; 99(6): 321-2. [PMID: 16821292]
17. Aronson JK, Ramachandran M. The diagnosis of art: melancholy and the *Portrait of Dr Gachet*. *J R Soc Med* 2006; 99(7): 373-4. [PMID: 22135838] [reprinted in *Meditheme* 2006; 25: 92-5].
18. Aronson JK, Ramachandran M. The diagnosis of art: exophthalmos—Gustave Doré's ogre. *J R Soc Med* 2006; 99(8): 421. [PMID: 16981319]
19. Ramachandran M, Aronson JK. The diagnosis of art: Rachmaninov's hand span. *J R Soc Med* 2006; 99(10): 529-30. [PMID: 17066567]
20. Ramachandran M, Aronson JK. The diagnosis of art: diastrophic dysplasia and Hephaistos. *J R Soc Med* 2006; 99(11): 584-5. [PMID: 22135839]
21. Ramachandran M, Aronson JK. The diagnosis of art: Lowry's gallery of cripples. *J R Soc Med* 2007; 100(3): 153-4. [PMID: 22135840]
22. Aronson JK, Ramachandran M. The diagnosis of art: Valentin le désossé and Ehlers–Danlos syndrome. *J R Soc Med* 2007; 100(4): 193-4. [PMID: 17563952]
23. Ramachandran M, Aronson JK. The diagnosis of art: Achilles Empereur and spondyloepiphyseal dysplasia congenita. *J R Soc Med* 2007; 100(8): 384-5. [PMID: 17821829]
24. Aronson JK, Ramachandran M. The diagnosis of art: Caravaggio's jaundiced Bacchus. *J R Soc Med* 2007; 100(9): 429-30. [PMID: 17941166]
25. Aronson JK, Ramachandran M. The diagnosis of art: Alice, the Duchess, Sir John Tenniel, foxgloves, and roses. *J R Soc Med* 2007; 100(12): 576-8. [PMID: 18229434]
26. Ramachandran M, Aronson JK. The diagnosis of art: Albrecht Dürer and the Christ Child's drooped shoulder. *J R Soc Med* 2008; 101(2): 87-8. [PMID: 22135841]
27. Aronson JK, Ramachandran M. The diagnosis of art: Dr Péan's operation. *J R Soc Med* 2008; 101(8): 423-4. [PMID: 18788145]
28. Aronson JK, Ramachandran M. The diagnosis of art: Millais' blind girl. *J R Soc Med* 2008; 101(11): 564-5. [PMID: 22135842]
29. Hughes N, Ramachandran M, Aronson JK. The diagnosis of art: Sir George Savile, 8th Baronet—the ears have it? *J R Soc Med* 2008; 101(12): 605-6. [PMID: 19108339]
30. Aronson JK, Ramachandran M. The diagnosis of art: Van Gogh and male pattern baldness. *J R Soc Med* 2009; 102(1): 32-3. [PMID: 19156985]
31. Aronson JK, Ramachandran M. The diagnosis of art: Durer's squint—and Shakespeare's? *J R Soc Med* 2009; 102(9): 391-3. [PMID: 22132457]
32. Aronson JK, Ramachandran M. The diagnosis of art: Scleroderma in Paul Klee—and Rembrandt's scholar? *J R Soc Med* 2010; 103(2): 70-1. [PMID: 22141181]
33. Aronson JK, Ramachandran M. The diagnosis of art: Ernst Ludwig Kirchner's 'nervous breakdown'. *J R Soc Med* 2010; 103(3): 112-3. [PMID: 20229643]
34. Aronson JK, Ramachandran M. The diagnosis of art: W H Auden's face. *J R Soc Med* 2011; 104(1): 38-40. [PMID: 22141182]
35. Ramachandran M, Aronson JK. Benjamin Brodie's infamous case of Isambard Kingdom Brunel and an inhaled gold coin. 1843. *J R Soc Med* 2011; 104(4): 149-54. [PMID: 21502213]
36. Ramachandran M, Aronson JK. Frederick Treve's first surgical operation for appendicitis. *J R Soc Med* 2011; 104(5): 191-7. [PMID: 21558097]
37. Ramachandran M, Aronson JK. John Bostock's first description of hay fever. *J R Soc Med* 2011; 104(6): 237-40. doi: 10.1258/jrsm.2010.10k056. [PMID: 21659398]
38. Ramachandran M, Aronson JK. John and James Parkinson's first description of acute appendicitis and its associated complications of perforation and death. *J R Soc Med* 2011; 104(7): 283-5. doi: 10.1258/jrsm.2010.10k057. [PMID: 21725093]
39. Ramachandran M, Aronson JK. The first description of hay fever? Response. *J R Soc Med* 2011; 104(9): 350.
40. Ramachandran M, Aronson JK. John Marshall's first description of surgical electrocautery. *J R Soc Med* 2011; 104(9): 355-60. [PMID: 21881086]
41. Ramachandran M, Aronson JK. Jacob Lockhart Clarke's and John Hughlings Jackson's first description of syringomyelia. *J R Soc Med* 2012; 105(2): 60-5. [PMID: 22357981]

J Book reviews etc

Many book, CD, radio, and television reviews in learned journals, including the BMJ, Lancet, New England Journal of Medicine, British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology, Neurochemistry International, Trends in Biochemical Science, and Medical History, including:

1. Aronson JK. Clinical chronopharmacology. Concepts, kinetics, application. *Br J Clin Pharmacol* 1991; 32(2): 263–4. [PMCID: PMC1368459]
2. Aronson JK. The Surgeon of Crowthorne: A tale of murder, madness and the love of words. *BMJ* 1998; 317(7163): 957. [PMID: 9756838]
3. Aronson JK. Windows shopping [Review of bookshops on the internet]. *BMJ* 1999; 318(7194): 1359 [full version at <http://bmj.com/cgi/content/full/318/7194/1359/DC1>]. [PMID: 10323845]
4. Aronson JK. A Dictionary of Pharmacology and Allied Topics (2nd edition). *Trends Pharmacol Sci* 1999; 20: 125.
5. Aronson JK. New Labour, New Language? *BMJ* 2000; 320(7247): 1480. [PMID: 10827065]
6. Aronson JK. Diamond is forever. *BMJ* 2001; 323(7307): 288. [PMCID: PMC1120899]
7. Aronson JK. The Words of Medicine: Sources, Meanings, and Delights. *BMJ* 2001; 323(7316): 813. [PMCID: PMC1121358]
8. Aronson JK. The Blood Doctor. *BMJ* 2002; 325(7375): 1307. [PMCID: PMC1124773]
9. Aronson JK. Dying for Drugs. *BMJ* 2003; 326(7396): 990. [PMCID: PMC1125906]
10. Aronson JK. One Man's Medicine. *BMJ* 2003; 327(7413): 507. [PMCID: PMC188412]
11. Aronson JK. The \$800 Million Pill: The Truth Behind the Cost of New Drugs. *BMJ* 2004; 329(7465): 577. [PMCID: PMC516126]
12. Aronson JK. Book review. Stephens' Detection of New Adverse Drug Reactions, 5th edn. *Br J Clin Pharmacol* 2004; 58(2): 227. [PMCID: PMC1884584]
13. Aronson JK. Book review. Stephens' Detection of New Adverse Drug Reactions, 5th edn. *Br J Clin Pharmacol* 2004; 58(2): 227.
14. Aronson JK. Book Review [Elsevier's Dictionary of Abbreviations, Acronyms, Synonyms and Symbols Used in Medicine, 2nd enlarged edition. Samuel A Tsur (Mansoor). Elsevier, 2004.] *Br J Clin Pharmacol* 2005; 59(1): 117. [PMCID: PMC1884961]
15. Aronson JK. The Doctor in Literature: Satisfaction or Resentment? *Health Expect* 2006; 9(2): 196–7.
16. Aronson JK. The Doctor in Literature: Volume 2, Private Life. *Health Expect* 2007; 10(3): 301–3.
17. Aronson JK. Phantastica. *BMJ* 2007; 334(7590): 429. [PMCID: PMC1804149]
18. Aronson JK. From Russia. French and Russian Master Paintings 1870–1925 from Moscow and St Petersburg. Royal Academy Main Galleries, 26 January to 18 April 2008. *Br J Gen Pract* 2008 58(548): 215.
19. Aronson JK. Book review. Adverse Drug Interactions: A Handbook for Prescribers. *Pharmacol Matters* 2010; 3(2): 21–2.
20. Aronson JK. Killing smoking. [Review of Smoking Kills: the Revolutionary Life of Richard Doll, by Conrad Keating. Signal Books, 2010.] *Lancet* 2011; 377(9762): 290.